

**CONSOLIDATED AUDITED FINANCIAL STATEMENTS
WITH SUPPLEMENTARY INFORMATION**

**ROSWELL PARK CANCER INSTITUTE
CORPORATION**

MARCH 31, 2014

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONTENTS

	<u>Page</u>
Independent Auditor's Report	1 - 2
Management's Discussion and Analysis	3 - 15
Financial Statements:	
Consolidated Statements of Net Position.....	16
Consolidated Statements of Revenues, Expenses and Changes in Net Position	17
Consolidated Statements of Cash Flows	18 - 19
Statements of Net Position – Component Unit	20
Statements of Revenues, Expenses and Changes in Net Position – Component Unit.....	21
Notes to the Consolidated Financial Statements	22 - 41
Supplemental Information:	
Independent Auditor's Report on Supplementary Information.....	42
Consolidating Statement of Net Position.....	43
Consolidating Statement of Revenues, Expenses and Changes in Net Position	44
Combining Statement of Net Position	45
Combining Statement of Revenues, Expenses and Changes in Net Position.....	46



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of the
Roswell Park Cancer Institute Corporation
Buffalo, New York

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Roswell Park Cancer Institute Corporation ("RPCIC" or "Corporation"), a component unit of New York State, which comprise the consolidated statements of net position as of March 31, 2014 and 2013, and the related consolidated statements of revenues, expenses, and changes in net position, cash flows and discretely presented component unit for the years then ended, and the related notes to the consolidated financial statements, which collectively comprise the Corporation's consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express opinions on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the respective net position of the Corporation and the aggregate discretely presented component unit as of March 31, 2014 and 2013, and the respective results of its operations and, where applicable, cash flows thereof for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As further discussed in Note 13, RPCIC had significant transactions with related parties. Our opinion is not modified with respect to this matter.

Other Matters

Required Supplementary Information

Accounting principles generally accepted in the United States of America, require that the management's discussion and analysis on pages 3 through 15 be presented to supplement the consolidated financial statements. Such information, although not a part of the consolidated financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the consolidated financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's response to our inquiries, the consolidated financial statements, and other knowledge we obtained during our audit of the consolidated financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated June 13, 2014 on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

Freed Maxick CPAs, P.C.

Buffalo, New York
June 13, 2014

ROSWELL PARK CANCER INSTITUTE CORPORATION MANAGEMENT'S DISCUSSION AND ANALYSIS

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

Our discussion and analysis of Roswell Park Cancer Institute Corporation's ("RPCIC") financial performance provides an overview of the financial activities for the fiscal year that ended on March 31, 2014. The consolidated financial statements of RPCIC include the accounts of the Roswell Park Cancer Institute Corporation and the Roswell Park Cancer Institute Clinical Practice Plan (also collectively referred to as the "Institute" and/or "RPCI"). Please read this management's discussion and analysis in conjunction with RPCIC's consolidated financial statements. Unless otherwise indicated, all dollar amounts are in thousands.

1. Introduction

Roswell Park Cancer Institute was established in 1898 on the principle of integrating clinical care, research and education focused solely on cancer. Dr. Roswell Park, a nationally prominent Buffalo surgeon, was perhaps the first to describe the importance of translational research in a cancer center when he wrote in 1904 that *"Only [through] a deliberate, well-planned, combined attack from various directions by means fitted for such work could real advances be made and [further] the relationship of laboratory work, clinical study and education must be closely associated"*. Dr. Park's commitment to patient care and the scientific study of cancer led to the establishment of a research facility and hospital unit which were recognized and partially funded by the State of New York in 1904; this was the first example of government support for cancer research in the world.

RPCI, the only National Cancer Institute ("NCI") designated cancer center in Upstate New York, consistently ranks among the NCI's top recipients of funding. In 2008, the Institute's NCI Cancer Center Support Grant ("CCSG", also known as the "core" grant) was reviewed and renewed by a site visit team of 22 nationally recognized experts in cancer research and treatment for another 5 years. This grant, which forms the foundation for Roswell's designation as an NCI comprehensive cancer center is in its 38th year of continuous funding by the NCI. Only two other cancer centers in the U.S. have held the designation, an important benchmark of excellence, for this length of time. A competitive renewal for this grant was submitted and the application was approved for funding by the NCI in May 2014. The funding will run for five years.

The Institute holds full accreditation from the Joint Commission on Accreditation of Healthcare Organizations ("JCAHO"), and its programs and services are also reviewed and accredited by numerous national bodies, including the Accreditation Council for Continuing Medical Education, Accreditation Council for Graduate Medical Education, American Dental Association – Dentistry and Maxillofacial Prosthetics, American Society of Histocompatibility and Immunogenetics, Association of American Blood Banks, the Commission on Cancer of the American College of Surgeons (with commendation) and FACT (Foundation for the Accreditation of Cellular Therapy) which has awarded a 3-year accreditation for RPCI's Blood and Marrow Transplantation Program (autologous & allogeneic bone marrow; peripheral blood progenitor cell transplantation, collection & processing).

RPCI has been recognized by various prestigious national organizations for its clinical care and research programs:

- Leapfrog Top Hospital For Patient Safety and Quality Care (2010, 2011, 2012)
 - 1 of 65 from a field of nearly 1,200 nationwide
- US News & World Report – Best Hospitals for Cancer (Top 50 in 2013, 2012, 2011 & 2010)
- AARP – Best Hospital for Cancer (1 of 8 named nationally)
- Nursing Magnet Designation (2010 - 5 year term)
 - Fewer than 6% of all hospitals nationally- 1st in WNY
- NCI - Cancer Immunotherapy Trials Network (1 of 27 in North America)

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

1. Introduction (Continued)

- First institution in the United States to be accredited as a Training Institute in Robot-Assisted Surgery by the Société Internationale d'Urologie (SIU)
- BlueCross BlueShield Association - Blue Distinction Center for Complex and Rare Cancers & Center for Transplants

RPCI's more than 3,200 employees include nearly 325 clinicians, scientists, and shared research resources professional staff. The interdisciplinary research programs – basic science, translational, and clinical – focus on six primary areas of investigation: Tumor Immunology and Immunotherapy, Cell Stress and Biophysical Therapies, Genetics, Genitourinary Cancers, Experimental Therapeutics, and Population Sciences.

Approximately 800 masters students, doctoral and post-doctoral trainees, including graduate students, post-doctoral research fellows, medical students, residents, and clinical fellows, are trained at Roswell Park annually, many enrolled with either the Roswell Park Graduate Division of the University at Buffalo or the UB Graduate School of Medicines Graduate Medical Education Programs. Roswell Park collaborates with a variety of the regions higher education institutions in the training of over 500 nurses, pharmacists, therapists and technologists and other health professionals annually.

Patient activity continued to grow with over 31,147 active patients diagnosed, treated, and/or seen in follow-up clinics and 199,960 outpatient visits in fiscal year 2014.

The Office of Cancer Health Disparities Research, unique among cancer centers nationally, is dedicated to research that advances the understanding of health disparities and to developing and offering integrated community-based services and educational programs tailored to meet the needs of these populations.

The RPCI campus is 29 acres located in the heart of the 110 acre Buffalo Niagara Medical Campus ("BNMC") near downtown Buffalo. The Facilities are comprised of 16 major buildings totaling nearly 2 million square feet of space of which more than 990,000 square feet is dedicated to research in the form of laboratory, laboratory support, office and shared resource space. Six of the buildings are utilized for wet/dry research and have new or renovated laboratory space. The RPCI clinical facilities (600,000 square feet) include a dedicated 133-bed cancer hospital and an ambulatory center with 12 multidisciplinary specialty clinics. Clinical services include a 14-bed Blood and Marrow Transplant Center and satellite ambulatory facilities in Amherst, NY and Niagara Falls, NY. The Pediatric Oncology/Hematology program, which includes a 9-bed inpatient/outpatient unit at RPCI, is a joint initiative with the Women and Children's Hospital of Buffalo delivering 90% of all hematology/oncology services for children in the 8-county WNY region for more than 30 years.

Community oncology care is delivered through both our RPCI Regional Affiliate Network and our Community Cancer Practice. Members include Cayuga Medical Center in Ithaca, NY; Bradford Regional Medical Center in Bradford, PA; Rochester General Hospital, Rochester, NY; Olean General Hospital, Olean, NY; Hematology Oncology Associates of CNY in East Syracuse, NY and Meadville Medical Center in Meadville, PA; and Jamestown Medical Oncology and Hematology in Jamestown, NY. In addition, Roswell Park runs the New York State Smoker's Quitline and the HIV/AIDS Hotline, which provide a wide variety of counseling and support services to individuals and public health professionals statewide.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

2. Mission

To understand, prevent and cure cancer.

Vision

To position Roswell Park Cancer Institute among the top 10 of the Nation's leading cancer centers.

Values

Core values reflect what is most true and important to us as an organization. These are values that have shaped us and will continue to – they do not change given circumstances or time but rather are consistent throughout our mission areas. RPCI is a special place to work and the staff and faculty who live these values have made it so. These values will guide and power our personal and collective actions and enable future successes on behalf of individuals and the world.

- **Innovation:** We are driven to provide care that cures and comforts, research that informs the world, and education that enlightens and enables future generations. We proudly stand on our rich history and use it as a platform from which to embrace discovery and change.
- **Integrity:** We are committed to making each decision, whether related to patient care, research, education or administration, based on standards that are thoughtful, informed, honest, transparent when appropriate and always respectful of privacy.
- **Teamwork:** We value and encourage the viewpoints and constructive opinions of all people and disciplines and recognize that all contributions strengthen the results we achieve, the value we provide, the actions we take and the team we strive to be.
- **Commitment:** We are devoted to achieving extraordinary progress on behalf of those we serve; patients and families who come to us during times of great need, scientists and clinicians who wish to collaborate, students seeking education, the science of cancer that awaits our contributions, and the community that deserves strong stewardship and economic leadership.
- **Compassion and Respect:** We are enriched by the diverse cultures, needs, and expectations of our coworkers and of the communities we serve. It is our privilege and responsibility to appreciate these differences as we establish research goals, develop care plans, and interact with one another.

3. Governance

Effective January 1, 1999, the Institute became a public benefit corporation of the State of New York ("NYS" or the "State"), operating under enabling legislation enacted under Title 4 of the Public Authorities Law. The Institute is owned by NYS and operated as a public benefit corporation ("PBC") and as such, is a component unit of NYS. Prior to January 1, 1999 the Institute was a division of the New York State Health Department. As a public benefit corporation, the Institute continues to adhere to the NYS public employees' collective bargaining agreements and is required to provide employee benefits consistent with the NYS Executive Branch.

4. Component Units

For purposes of the financial statements, the Roswell Park Alliance Foundation, Inc. (the "Foundation") is considered a "component unit" of RPCIC. The Foundation was established in March 1991 to solicit, receive and administer funds to support scientific and clinical research, delivery of state-of-the-art medical care and treatment, and patient-related activities at Roswell Park Cancer Institute. The Foundation is tax exempt under Section 501(C)(3) of the Internal Revenue Code and is managed by a Board of Trustees of community leaders. This Board is independent of the RPCIC Board of Directors and as such, RPCIC's Board has no jurisdiction over the Board of the Foundation or the Foundation's assets. Periodically, the Foundation makes grants to RPCIC for various purposes. These grant funds are typically administered by Health Research, Incorporated.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013
(in thousands of dollars, except as otherwise noted)

4. Component Units (Continued)

In November 2010, GASB issued *Statement No. 61, The Financial Reporting Entity: Omnibus an amendment of GASB Statements No. 14 and No. 34*. Statement 61 modifies certain requirements relating to the inclusion of component units within the financial reporting entity. GASB Statement No. 61 is effective for financial statement periods beginning after June 15, 2012. RPCIC adopted the provisions of the statement in 2013 on a retroactive basis. The adoption of GASB Statement No. 61 requires that the component unit's financial statements be presented discretely from the financial statements of the Corporation. The Corporation has elected to present the Foundation component unit's financial statements immediately after the Corporation's consolidated financial statements, included in the basic financial statements.

In addition, the consolidated financial statements of the Institute also include financial results of the Institute's blended component units, RPCI Oncology, P.C. and Carlton & Michigan, LLC ("C&M").

5. Financial Highlights

- Net position increased \$1,050 (0.8%) from 2013 to 2014 and decreased \$8,225 (5.8%) from 2012 to 2013.
- Total assets increased \$66,769 (9.1%) from 2013 to 2014 and \$43,209 (6.3%) from 2012 to 2013.
- Operating revenues excluding NYS support increased by \$18,993 (4.4%) from 2013 to 2014 and \$50,184 (13.1%) from 2012 to 2013.
- NYS support revenue remained constant at \$77,600 in 2014 and 2013.
- Operating expenses increased by \$19,485 (3.6%) from 2013 to 2014 and \$49,371 (10.1%) from 2012 to 2013.

6. Using This Annual Report

RPCIC's consolidated financial statements consist of three statements – a consolidated statement of net position; a consolidated statement of revenues, expenses and changes in net position; and a consolidated statement of cash flows. These statements provide information about RPCIC's activities including resources held by RPCIC but restricted for specific purposes by contributors, grantors, or enabling legislation.

The Statement of Net Position and the Statement of Revenues, Expenses and Changes in Net Position

Both statements report information about RPCIC's resources and its activities that describe the financial results of the fiscal year and RPCIC's net position as of the end of the year. They also report RPCIC's net position and changes in it.

Net position is the difference between assets and liabilities. Over time, increases or decreases in RPCIC's net position is one indicator of whether RPCIC's financial health is improving, or deteriorating. Other non-financial factors such as changes in RPCIC's patient base, measure of the quality of services provided, local, state and federal economic factors should also be considered.

The Statement of Cash Flows

The statement reports cash receipts, cash payments and net changes in cash resulting from operations, investing and financing activities. It describes sources of cash, uses of cash and the change in cash balance during the fiscal year.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

7. Related Parties

Health Research, Incorporated

Health Research, Inc. ("HRI") is a not-for-profit corporation chartered under the laws of NYS in 1953 primarily to administer gifts or grants in keeping with the research, prevention, and treatment purposes of the New York State Department of Health ("NYSDOH"). HRI has divisions in Buffalo and Albany, New York which administer projects conducted at the NYSDOH and the Roswell Park Cancer Institute primarily financed by private and governmental contracts, grants and donations. HRI is tax exempt under Section 501(C)(3) of the Internal Revenue Code. HRI is not included in the RPCIC consolidated financial statements, however is considered a related party for financial reporting purposes.

8. RPCIC's Net Position

RPCIC's net position is the difference between the assets and liabilities reported in the statement of net position. RPCIC's net position increased by \$1,050 in 2014 and decreased by \$8,225 in 2013 as shown in Table 1. The reasons for these changes are discussed below. Changes in capital assets and long-term debt are also discussed under the heading *Capital Asset and Debt Administration*.

Table 1: Summary of Statement of Net Position

	<u>2014</u>	<u>2013</u>	<u>2012</u>
Assets:			
Current and other assets	\$ 500,803	\$ 439,944	\$ 399,180
Capital assets, net	<u>297,537</u>	<u>291,627</u>	<u>289,182</u>
Total assets	<u>\$ 798,340</u>	<u>\$ 731,571</u>	<u>\$ 688,362</u>
Liabilities:			
Long-term debt outstanding	\$ 236,894	\$ 220,762	\$ 229,473
Other liabilities	<u>426,743</u>	<u>377,156</u>	<u>317,011</u>
Total liabilities	<u>663,637</u>	<u>597,918</u>	<u>546,484</u>
Net Position:			
Net investment in capital assets	93,515	92,997	81,919
Restricted expendable	56,795	67,303	51,677
Unrestricted	(15,605)	(26,647)	8,282
Noncontrolling interest	<u>(2)</u>	<u>-</u>	<u>-</u>
Total net position	<u>134,703</u>	<u>133,653</u>	<u>141,878</u>
Total liabilities and net position	<u>\$ 798,340</u>	<u>\$ 731,571</u>	<u>\$ 688,362</u>

Overall, total assets increased \$66,769 from 2013 to 2014 and \$43,209 from 2012 to 2013.

- Current and other assets increased 13.8% in 2014, and 10.2% in 2013 as compared to 2012. This is due to an increase in limited use assets. In addition, non current assets in 2014 include \$21,261 in notes receivable related to the funding of the CSC construction.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

8. RPCIC's Net Position (Continued)

- Capital assets, net increased 2.0% from 2013 to 2014 and 0.8% from 2012 to 2013 driven by the timing of capital additions, net of depreciation. Specifically, the timing of capital additions is driven by funding priorities and the availability of Heal NY grants of \$25,000 for capital purchases in 2014 and 2013. This funding was unavailable in 2012.

Overall, total liabilities increased 11.0% from 2013 to 2014 and 9.4% from 2012 to 2013.

- Other liabilities increased 13.1% in 2014 primarily due to a 15.8% increase in the post retirement health liability, a 30.1% increase in accrued malpractice, and recognition of \$6,027 of unearned revenue received from the Foundation to fund the Clinical Science Center ("CSC") building.
- Other liabilities increased 19.0% in 2013 primarily due to a 19.3% increase in the post retirement health liability, a 65.7% increase in liabilities to third party payors, and a 39.7% increase in accounts payable and other current liabilities due to the timing of payments to vendors.
- Long-term debt outstanding increased 7.3% in 2014 and decreased 3.8% in 2013. The increase in 2014 is driven by new loans of \$29,780 to fund the construction of the CSC. In 2013, the decrease was a result of scheduled debt service payments on the outstanding DASNY issued debt and the amortization of bond premium partially offset by an increase of \$4,523 due to a capital lease for the rental of employee parking spaces in the MiGo parking ramp.

Overall, total net position increased 0.8% from 2013 to 2014 and decreased by 5.8% from 2012 to 2013.

9. Changes in RPCIC's Net Position

The following summarizes RPCIC's statement of revenue, expenses and changes in net position between 2014, 2013 and 2012.

Patient volumes at RPCIC are measured on both the inpatient and outpatient basis. Inpatient admissions decreased 11.3% from 2013 to 2014 and 2.0% from 2012 to 2013. Inpatient days decreased to 38,243 (2.0%) in 2014 and increased to 39,005 (7.8%) in 2013 from 36,186 in 2012. Outpatient visits decreased to 199,960 (2.2%) in 2014 but increased to 204,450 (1.4%) in 2013 from 201,554 in 2012.

In 2014 RPCIC's net position increased by \$1,050 (0.8%) as shown in Table 2. Operating revenues excluding NYS support increased 4.4% and operating expenses grew 3.6%. The operating expense base of \$556,774 includes annual OPEB cost of \$48,376 and an annual pension cost of \$25,284 in 2014. Both of these employee fringe benefits are required to be provided by the PBC. See "Matters Involving New York State" in Note 8 and the "New York State" section in Note 13. Total support from NYS remained unchanged from 2013.

In 2013 RPCIC's net position decreased by \$8,225 (5.8%) as shown in Table 2. While operating revenues excluding NYS support grew a healthy 13.1%, this was not sufficient to cover a 10.1% growth in operating expenses. The operating expense base of \$537,289 includes annual OPEB cost of \$48,763 and an annual pension cost of \$20,344 in 2013. Both of these employee fringe benefits are required to be provided by the PBC. See "Matters Involving New York State" in Note 8 and the "New York State" section in Note 13. Total support from NYS returned to the level of support provided in 2011, an increase of \$25,000 over 2012 levels.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

9. Changes in RPCIC's Net Position (Continued)

Table 2: Summary of Revenues, Expenses and Changes in Net Position

	<u>2014</u>	<u>2013</u>	<u>2012</u>
Operating revenues:			
Net patient service revenue and net settlement and appeals	\$ 439,230	\$ 420,822	\$ 370,172
NYS support	77,600	77,600	77,600
Grants and contracts	1,554	1,762	2,075
Other operating revenue	<u>10,240</u>	<u>9,446</u>	<u>9,599</u>
Total operating revenues	<u>528,624</u>	<u>509,630</u>	<u>459,446</u>
Operating expenses:			
Salaries, wages and benefits	309,654	300,038	282,356
Purchased services and supplies	202,318	196,246	168,770
Provision for malpractice	9,870	5,656	1,840
Depreciation and amortization	<u>34,932</u>	<u>35,349</u>	<u>34,952</u>
Total operating expenses	<u>556,774</u>	<u>537,289</u>	<u>487,918</u>
Operating loss	(28,150)	(27,659)	(28,472)
Non-operating revenues and expenses and changes in net position			
	<u>29,200</u>	<u>19,434</u>	<u>(7,980)</u>
Increase (decrease) in net position	\$ <u>1,050</u>	\$ <u>(8,225)</u>	\$ <u>(36,452)</u>

Overall, operating revenues excluding NYS support increased 4.4% from 2013 to 2014 and 13.1% from 2012 to 2013.

- Net patient service revenue including settlements and appeals increased 4.4% in 2014 and 13.7% in 2013 as a result of the following: RPCIC hospital revenue increased 4.6% and 11.3% and professional revenues increased 9.4% and 1.6% in 2014 and 2013, respectively. Government appeals and settlement revenue decreased 25.6% in 2014 but increased 141.0% in 2013. The increases in hospital and professional revenues were attributable to changes in mix of services provided as well as third party payor rate increases. The increases/decreases in the government appeals and settlements revenue were due to fluctuations in revenue from DSH cap adjustments, and Medicare settlements and appeals. Revenues also include \$4,738 and \$1,325 related to RPCI Oncology, PC for 2014 and 2013, respectively.
- Grant and contract revenues include salary recovery on grants administered through HRI for work by the medical staff whose salaries are paid by the Institute. In 2010, RPCIC changed its policy and allowed salary recovery on research staff to be retained by HRI as part of the overall contribution to HRI. This amounted to approximately \$3,668 and \$3,994 in 2014 and 2013.
- Other operating revenue increased 8.4% from 2013 to 2014 and decreased 1.6% from 2012 to 2013. Other operating revenues include revenues received from the operation of the cafeteria, parking garage, and other ancillary activities. See "Other operating revenue" section in Note 2.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

9. Changes in RPCIC's Net Position (Continued)

Overall, operating expenses increased 3.6% from 2013 to 2014 and 10.1% from 2012 to 2013.

- Salary, wages, and benefits costs increased 3.2% and 6.3%, respectively, due to:
 - Growth in employee benefits and retiree health expense including increases in retirement costs, health insurance costs, worker's compensation, and other employee benefits. Benefits were 59.6%, 57.5%, and 57.0%, of salary costs in 2014, 2013 and 2012, respectively.
 - Step and cost of living increases required by labor contracts.
 - Recruitment of scientific and clinical faculty as well as staffing increases related to changes in patient acuity and new initiatives.
- Purchased services and supplies increased 3.1% and 16.3%, respectively, due to:
 - Variable cost increases related to inflation and patient volume/mix affecting pharmaceuticals, blood and blood products, medical supplies, and certain purchased services.
 - Recording of a reserve in 2013 for a receivable from NYS.
 - Increased cost of utilities.

Nonoperating revenues (expenses) and changes in net position increased 50.3% from 2013 to 2014 due to the following factors:

- Contributions for purchases of capital assets in 2014 include \$7,851 from the Foundation to fund CSC construction, \$2,550 received from ESDC to fund the Center for Personalized Medicine ("CPM"), and grant income administered through HRI in the amount of \$1,557 for renovation of the Grace Cancer Drug Center ("GCDC"). Funding in the amount of \$25,000 was received from HEAL NY in 2014 consistent with 2013.
- Interest and other income decreased 29.3% due to a decline in interest rates.
- Interest expense has declined 3.7% from 2014 to 2013. This is due primarily to the effect of the scheduled debt payments and amortization of bond premium.

Nonoperating revenues (expenses) and changes in net position increased 100.0+% from 2012 to 2013 due to the following factors:

- The \$25,000 funding from HEAL NY was restored in 2013. This funding was not provided by NYS in 2012. Contributions for purchases of capital assets in 2013 also include grant income administered through HRI in the amount of \$2,014 for renovation of the Grace Cancer Drug Center ("GCDC").

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

9. Changes in RPCIC's Net Position (Continued)

- Interest and other income decreased 18.8% due to a decline in interest rates.
- Interest expense has declined 4.7% from 2013 to 2012. This is due primarily to the effect of the scheduled debt payments and amortization of bond premium.
- In 2012, a loss of \$1,308 was incurred on the issuance of the Series 2011A debt, which refinanced the Series 1998 bond indebtedness.

10. Capital Asset and Debt Administration

At the end of fiscal 2014, 2013 and 2012, RPCIC had \$297,537, \$291,627, and \$289,182, respectively, invested in capital assets, net of accumulated depreciation, as detailed in Note 4 to the consolidated financial statements. The components of RPCIC's capital assets are as follows:

Capital Assets

	<u>2014</u>	<u>2013</u>	<u>2012</u>
Land	\$ 4,292	\$ 4,292	\$ 4,292
Building	504,260	499,741	492,488
Equipment/other	194,592	189,072	170,021
Construction in progress	<u>41,051</u>	<u>16,083</u>	<u>7,046</u>
	744,195	709,188	673,847
Less: Accumulated depreciation	<u>(446,658)</u>	<u>(417,561)</u>	<u>(384,665)</u>
Net capital assets	<u>\$ 297,537</u>	<u>\$ 291,627</u>	<u>\$ 289,182</u>

During May 2013, Carlton & Michigan, LLC ("C&M") was established to construct and operate a new Clinical Science Center ("CSC" or the "Project"). C&M is jointly owned by RPCIC (90%) and the Foundation (10%). During 2014, construction began on the CSC, on the grounds of the Institute at the corner of Carlton and Michigan Streets in the City of Buffalo, NY. The CSC building will connect to the Main Hospital and the GCDC which is being transformed into the Translational Research Center to house researchers converting basic research into clinical applications. RPCIC will be the sponsor and developer of the Project. RPCIC has committed approximately \$10,000 of Board Designated Funds towards the construction of the project. In addition, the Foundation has met their goal and secured all of the \$25,000 in pledges for the CSC capital campaign, as well as committed approximately \$5,000 in the form of additional funding for the project. Other financing structures for the project are described more fully in Section 11. The CSC is expected to be complete in fiscal 2016.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

10. Capital Asset and Debt Administration (Continued)

Long Term Debt and Capital Leases

RPCIC's outstanding long term bonds payable (net of applicable discounts and premiums) were \$224,036, \$208,514, and \$217,771 as of March 31, 2014, 2013, and 2012, respectively. This represents the Institute's allocated portions of certain New York State Department of Health outstanding bonds payable to DASNY. All bonds are collateralized by a first lien on the revenues of the Institute.

	<u>2014</u>	<u>2013</u>	<u>2012</u>
Series 2003 Bonds, net of premium	\$ 23,360	\$ 25,461	\$ 27,488
Series 2004 Bonds, net of premium	95,064	104,487	113,600
Series 2005 Bonds, net of premium	48,974	49,141	49,303
Series 2011A Bonds, net of premium	35,184	37,150	39,082
Notes Payable	29,780	-	-
Capital leases	<u>4,532</u>	<u>4,523</u>	<u>-</u>
Total long-term debt and capital lease obligations, net	236,894	220,762	229,473
Less: Current portion	<u>(12,858)</u>	<u>(12,248)</u>	<u>(11,702)</u>
Non-current portion	<u>\$ 224,036</u>	<u>\$ 208,514</u>	<u>\$ 217,771</u>

During fiscal 2014, Carlton & Michigan, LLC secured notes payable in the amount of \$29,780 from several Community Development Entities to fund construction of the CSC and to garner the benefit of certain New Market Tax Credits. See section 11 below for full details of this transaction.

During July 2011, DASNY refinanced certain long-term obligations in which RPCIC was a partial beneficiary on the original issue (Series 1998 Bonds). The refinancing resulted in the lowering of interest rates on RPCIC's long term obligation as well as the reduction of the long term debt balance by \$2,375. The net present value of savings on the refinancing is approximately \$3,551. In connection with the refinancing, a loss of \$1,308 was recognized in fiscal 2012. Included in this loss is \$707 of unamortized bond discount and \$213 of accelerated amortization of original bond issue costs.

On December 10th, 2010 (amended January 9th, 2011), RPCIC entered into an agreement with 134 High Street, LLC, owner and operator of the MiGo parking ramp on High Street, to lease 226 parking permits in said ramp commencing upon issuance of the Certificate of Occupancy ("C of O") by the City of Buffalo. The term of the lease is for 35 years with the ability to renew for 2 additional 7 year terms on the same terms and conditions. RPCIC's future obligations related to these permits include monthly lease payments to be applied to certain costs of the ramp including debt payments and operating expenses. The C of O was obtained and the lease commenced in June 2012. RPCIC has capitalized \$4,513 related to this lease in fiscal 2013.

11. Financing for the Clinical Science Center

The Corporation, C&M and the Foundation are all parties to a series of transactions entered into to finance the construction of the CSC. By consummating these transactions, the Corporation will be able to garner the benefit of certain New Market Tax Credit (NMTC) enhanced financing to partially fund the construction of the CSC. The NMTC program was established pursuant to federal legislation in the year 2000 and is administered through the CDFI Fund of the United States Department of the Treasury. The purpose of the NMTC program is to provide an incentive for businesses to invest in projects being built or operated in low income communities. To be considered eligible, various criteria must be met pertaining to the project itself (in this case, the construction and operation of the CSC), as well as the participating entities themselves (in this case, the Corporation, C&M, the Foundation and certain other unrelated investor entities). Further information on the New Market Tax Credit program can be found at www.cdfifund.gov.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

11. Financing for the Clinical Science Center (Continued)

Under the program, participating NMTC investors will receive a maximum 39% tax credit over a period of seven years on qualified equity investments totaling approximately \$30.5 million made in the construction of the CSC. Through its participation in the NMTC program, RPCIC expects to recognize a net benefit from the program of approximately \$6.2 million, which represents the NMTC investors' equity investment in the tax credits less all fees and expenses.

Pursuant to the laws and regulations surrounding the NMTC program, several entities are party to the overall financing plan. RPCIC leveraged its own funds (both internal equity and funds raised by the RPAF through a capital campaign), a portion of which were loaned to two unrelated NMTC investment funds. These NMTC investment funds then made qualifying equity contributions into various Community Development Entities (CDEs), which in turn loaned those funds as qualified low-income community investments to C&M to fund the construction of the CSC. The following recaps the amounts recognized in the consolidated statement of net position as of March 31, 2014:

	Asset (Liability)
Notes Receivable: RPCIC funds loaned to NMTC investment funds	\$ 21,261
Notes Payable: Amounts borrowed by C&M from CDEs to fund construction of the CSC	\$ (29,780)

The NMTC program requires the financing structure to remain in place for a period of not less than seven (7) years from the date in which the NMTC investment funds make the qualified equity investment into the CDEs (the "Compliance Period"). During the Compliance Period, C&M makes interest-only payments on the loans from the CDEs. The CDEs use the interest payments to pay fees and distribute the remaining proceeds to the NMTC Investment Funds. The NMTC investment funds then use the proceeds to make interest-only payments on their notes payable to RPCIC. At the conclusion of the Compliance Period, the investors in the NMTC investment funds have the option to have their interest in the CDEs redeemed, which will result in the CDEs assigning their assets to the NMTC investment funds, including the Notes Receivable from C&M.

Additionally, the NMTC Investors have the option to put their interest in the NMTC investment funds to RPCIC for a price of \$1,000. If the NMTC Investors do not exercise their put options, RPCIC may exercise a call option to purchase the NMTC Investors' interests in the NMTC investment funds for a price equal to the fair market value of the interests. Exercise of either the put or call options will effectively transfer ownership of the NMTC investment funds to RPCIC, which will allow RPCIC to cancel the loans between the NMTC investment funds and C&M. Recognition of the estimated \$6.2 million NMTC net benefit, represented as the difference in value of the NMTC investment interests and the loans payable to the CDEs at the end of the Compliance Period, is contingent upon the exercise of either the put or call options, and thus is considered a gain contingency. Recognition of the NMTC benefit is therefore deferred until such time as the put or call options are exercised, which is expected to be no sooner than the expiration of the Compliance Period in September, 2020.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013
(in thousands of dollars, except as otherwise noted)

12. Postemployment Benefits

Effective April 1, 2006, RPCIC early adopted the provisions of GASB Statement No. 45, *Accounting and Financial Reporting by Employers for Postemployment Benefits Other than Pensions*. Statement 45 establishes standards for the measurement, recognition, and display of Other Postemployment Benefits ("OPEB") expense/expenditures and related liabilities (assets), note disclosures, and, if applicable, required supplementary information in the financial reports of state and local governmental employers.

Funded Status and Funding Progress

The most recent actuarial valuation for the OPEB plan was April 1, 2013. As of March 31, 2014 the OPEB plan was unfunded. As discussed below in the section titled "Matters Involving New York State", RPCIC is seeking relief from NYS for all or a significant portion of the unfunded OPEB liability. RPCIC believes it will need some form of assistance from NYS in order to meet future OPEB obligations resulting from the benefits that have, and will continue to, accrue under the OPEB plan. The actuarial accrued liability ("AAL") for benefits was \$587,473 and the actuarial value of assets was \$0, resulting in an unfunded actuarial accrued liability (UAAL) of \$587,473. The covered payroll (annual payroll of active employees covered by the plan) was \$192,131, and the ratio of the UAAL to the covered payroll was 305.77 percent.

Actuarial valuations of an ongoing plan involve estimates of the value of reported amounts and assumptions about the probability of occurrence of events far into the future. Examples include assumptions about future employment, mortality, and the healthcare cost trend. Amounts determined regarding the funded status of the plan and the annual required contributions of the employer are subject to continual revision as actual results are compared with past expectations and new estimates are made about the future.

Actuarial Method and Assumptions

Projections of benefits for financial reporting purposes are based on the substantive plan (the plan as understood by the employer and the plan members) and include the types of benefits provided at the time of each valuation and the historical pattern of sharing of benefit costs between the employer and plan members to that point. The actuarial methods and assumptions used include techniques that are designed to reduce the effects of short-term volatility in actuarial accrued liabilities and the actuarial value of assets, consistent with the long-term perspective of the calculations.

In 2014 and 2013, the actuarial valuations utilized the entry age normal cost method. The actuarial assumptions included a 3.0 percent investment rate of return, which is the expected long-term investment return on the employer's investments and an annual healthcare cost trend rate of 8.0 percent reduced by decrements to an ultimate rate of 5.0 percent in 2024. 2014 and 2013 included a 2.5 percent inflation assumption. The assumed rate of annual salary increase is 3.5 percent and 5.0 percent in 2014 and 2013, respectively. The UAAL is being amortized as a level dollar of projected payroll on an open basis. The remaining amortization period at March 31, 2014, was twenty-two years.

Matters Involving New York State

RPCIC has recognized in its consolidated statement of net position and consolidating statement of revenues, expenses and changes in net position the amounts described above. In so doing, RPCIC has assumed that it will be liable for the portion of benefits attributable to services provided by its employees for the period prior to January 1, 1999, the date at which RPCIC became a public benefit corporation of the State of New York. As discussed, RPCIC is seeking relief from NYS for all or a significant portion of the unfunded OPEB liability. RPCIC believes it will need some form of assistance from NYS in order to meet future OPEB obligations resulting from the benefits that have, and will continue to, accrue under the plan.

**ROSWELL PARK CANCER INSTITUTE CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS**

MARCH 31, 2014 and 2013

(in thousands of dollars, except as otherwise noted)

12. Postemployment Benefits (Continued)

If NYS were to agree to assume all of the benefits for the time period it operated Roswell Park (e.g. prior to 1/1/99), RPCIC would have the potential to recognize the reduction in its accrued liability for any amounts of that liability to which the State would agree to accept.

The following table illustrates the actuarially-derived estimates of the postemployment benefit liability and associated cost for March 31, 2014, utilizing a cutoff date of January 1, 1999:

	<u>Prior to January 1, 1999</u>	<u>Post January 1, 1999</u>	<u>Total</u>
Actuarial accrued liability (AAL)	\$ 141,463	\$ 446,010	\$ 587,473
Annual required contribution (ARC)	7,066	46,982	54,048
Annual OPEB cost	6,334	42,042	48,376
Net OPEB obligation:			
Net OPEB obligation – beginning of year	34,866	235,028	269,894
Annual OPEB cost	6,334	42,042	48,376
Employer contributions	<u>(3,337)</u>	<u>(2,326)</u>	<u>(5,663)</u>
Net OPEB obligation – end of year	<u>\$ 37,863</u>	<u>\$ 274,744</u>	<u>\$ 312,607</u>

13. Financial Condition

The Corporation is reliant upon the on-going financial support of the State in the furtherance of its mission, particularly in support of the Institute's research operations. In 2014 and 2013, total support received from the State amounted to approximately \$102,600, as compared to approximately \$77,600 in 2012. In fiscal 2014 and 2013, \$25,000 of this support was funded through the HEAL NY program. The HEAL NY monies were required to be used for capital expenditures for each year. Effective for fiscal year 2015, the State budget includes up to approximately \$102,600 in total support for RPCIC. This appropriation is not contingent on utilization for capital expenditures.

In fiscal 2013, the NYS budget included the following language: (Roswell is directed) "to take all necessary and appropriate steps and arrangements to develop a plan and, on or before January first, two thousand fourteen, seek the necessary approvals to execute such plan which may include but are not limited to entering into arrangements, mergers or other affiliations with one or more healthcare, academic or other entities for the purpose of protecting and promoting the health of the patients served by its health facilities, advancing the corporation's mission of conducting innovative research into the causes and treatment of cancer, securing its financial viability and achieving operational and fiscal independence from the state, and to the extent possible, contributing to the economic revitalization of the region; provided that the commissioner of health shall monitor such steps and arrangements and participate with the corporation in establishment of goals and benchmarks for the achievement of such independence, and the corporation shall make requests for assistance and approvals needed to execute such steps and arrangements." In fiscal 2013, RPCIC began a Strategic Transformation project with the goal of meeting the requirements of the above mentioned legislation.

The continued challenges faced by the State in its fiscal and budgetary matters present increased uncertainty with respect to whether the State will continue to provide support to the Corporation at a level consistent with 2014 and prior. Without the continued level of support, the Corporation will need to invest in its property and equipment through operating cash flow, new indebtedness or other means. An additional significant risk to the financial condition is the anticipated increasing future cash outlay for payment of post-employment health benefits.

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONSOLIDATED STATEMENTS OF NET POSITION

March 31,

ASSETS	2014	2013
Current assets:		
Cash and cash equivalents	\$ 131,775,551	\$ 151,344,143
Current portion of assets limited as to use	51,190,610	38,557,307
Patient accounts receivable, net of estimated uncollectibles of approximately \$23,657,000 in 2014 and \$22,597,000 in 2013	56,513,776	54,971,263
Inventories	5,016,323	5,000,044
Due from New York State and other affiliates	2,431,732	1,779,846
Prepaid expenses and other assets	4,323,476	5,291,374
Total current assets	<u>251,251,468</u>	<u>256,943,977</u>
Non-current assets:		
Due from affiliates	505,099	505,099
Assets limited as to use, net	226,721,248	181,333,623
Intangible assets	1,065,138	1,161,806
Notes receivable	21,260,833	-
Capital assets, net	<u>297,536,670</u>	<u>291,626,981</u>
Total non-current assets	<u>547,088,988</u>	<u>474,627,509</u>
Total assets	<u><u>\$ 798,340,456</u></u>	<u><u>\$ 731,571,486</u></u>
LIABILITIES AND NET POSITION		
Current liabilities:		
Current portion of long-term obligations	\$ 12,858,331	\$ 12,248,532
Accounts payable and other current liabilities	19,824,230	21,006,715
Accrued expenses	82,477,894	77,102,211
Unearned revenue	6,027,244	-
Due to third-party payors	<u>12,304,222</u>	<u>15,163,175</u>
Total current liabilities	<u>133,491,921</u>	<u>125,520,633</u>
Long-term obligations, net of current portion	224,035,585	208,513,713
Post-employment benefits, net of current portion	<u>306,109,310</u>	<u>263,883,933</u>
Total liabilities	663,636,816	597,918,279
Net position:		
Net investment in capital assets	93,514,929	92,997,172
Restricted expendable	56,795,305	67,302,596
Unrestricted	<u>(15,604,314)</u>	<u>(26,646,561)</u>
Total Corporation net position	134,705,920	133,653,207
Noncontrolling interest	<u>(2,280)</u>	<u>-</u>
Total net position	<u>134,703,640</u>	<u>133,653,207</u>
Total liabilities and net position	<u><u>\$ 798,340,456</u></u>	<u><u>\$ 731,571,486</u></u>

See accompanying notes.

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONSOLIDATED STATEMENTS OF REVENUES, EXPENSES AND CHANGES IN NET POSITION
For the Years Ended March 31,

	<u>2014</u>	<u>2013</u>
Operating revenues:		
Net patient service revenue	\$ 423,107,639	\$ 399,157,736
Net settlements and appeals	16,122,590	21,663,774
New York State support	77,600,000	77,600,000
Grants and contracts	1,553,541	1,762,031
Other operating revenue	10,239,617	9,446,360
Total operating revenues	<u>528,623,387</u>	<u>509,629,901</u>
Operating expenses:		
Salaries and wages	193,999,640	190,519,215
Employee benefits	115,654,459	109,518,784
Supplies and other services	202,317,457	196,245,671
Depreciation and amortization	34,932,238	35,348,712
Provision for malpractice	9,870,041	5,656,581
Total operating expenses	<u>556,773,835</u>	<u>537,288,963</u>
Loss from operations	(28,150,448)	(27,659,062)
Nonoperating revenues (expenses):		
Interest and other income	1,040,251	1,472,140
Interest expense	(8,787,825)	(9,127,676)
(Loss) gain on disposal of capital assets	(11,869)	20,234
Investment loss	(168,551)	(44,596)
Net nonoperating expenses	<u>(7,927,994)</u>	<u>(7,679,898)</u>
Deficiency of revenues over expenses	(36,078,442)	(35,338,960)
Contributions for purchase of capital assets	37,128,875	27,113,834
Increase (decrease) in net position	1,050,433	(8,225,126)
Net position, beginning of year	<u>133,653,207</u>	<u>141,878,333</u>
Net position, end of year	<u>\$ 134,703,640</u>	<u>\$ 133,653,207</u>

See accompanying notes.

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years Ended March 31,

	<u>2014</u>	<u>2013</u>
Cash flows from operating activities:		
Net patient service revenue	\$ 434,828,763	\$ 423,941,459
New York State support	77,600,000	77,600,000
Grants and contracts	1,553,541	1,762,031
Other operating revenue	9,587,731	11,581,796
Payments to employees	(265,852,888)	(255,314,964)
Payments to vendors	(203,776,889)	(191,561,193)
Payments for malpractice	(4,841,626)	(2,089,588)
Net cash provided by operating activities	<u>49,098,632</u>	<u>65,919,541</u>
Cash flows from capital and related financing activities:		
Purchase of capital assets	(55,990,717)	(33,242,621)
Acquisition of intangible assets	-	(1,190,000)
Contributions for purchase of capital assets	37,128,875	27,113,834
Proceeds from financing	29,780,000	-
Repayment of long-term obligations	(12,239,172)	(11,701,955)
Payments of interest	(10,196,982)	(9,167,484)
Net cash used in capital and related financing activities	<u>(11,517,996)</u>	<u>(28,188,226)</u>
Cash flows from investing activities:		
Assets limited as to use, net	(58,020,928)	(19,779,919)
Interest and investment income	871,700	1,427,544
Net cash used in investing activities	<u>(57,149,228)</u>	<u>(18,352,375)</u>
Net (decrease) increase in cash and cash equivalents	(19,568,592)	19,378,940
Cash and cash equivalents - beginning of year	<u>151,344,143</u>	<u>131,965,203</u>
Cash and cash equivalents - end of year	<u>\$ 131,775,551</u>	<u>\$ 151,344,143</u>

See accompanying notes.

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

For the Years Ended March 31,

	<u>2014</u>	<u>2013</u>
Reconciliation of loss from operations to net cash provided by operating activities:		
Loss from operations	\$ (28,150,448)	\$ (27,659,062)
Adjustments to loss from operations to net cash provided by operating activities:		
Depreciation and amortization	34,932,238	35,348,712
Provision for bad debts	5,252,043	5,793,408
Changes in assets and liabilities:		
Patients accounts receivable	(6,794,556)	(8,687,179)
Inventories	(16,279)	(932,337)
Due from New York State and other affiliates	(651,886)	2,115,202
Prepaid expenses and other assets	967,898	(204,137)
Accounts payable and other	(1,182,485)	5,970,121
Accrued expenses and postemployment benefits	47,601,060	48,161,093
Due to third-party payors	(2,858,953)	6,013,720
Net cash provided by operating activities	<u>\$ 49,098,632</u>	<u>\$ 65,919,541</u>

See accompanying notes.

ROSWELL PARK CANCER INSTITUTE CORPORATION

STATEMENTS OF NET POSITION - COMPONENT UNIT

March 31,

ASSETS	Roswell Park Alliance Foundation, Inc.	
	2014	2013
Current assets:		
Cash and cash equivalents	\$ 17,038,790	\$ 24,574,987
Investments, at fair value	5,262,855	4,696,839
Gifts and pledges receivable, current	5,832,818	5,805,993
Inventories	71,509	59,386
Due from affiliates	978,537	476,014
Advance funded grant to affiliate	5,027,243	-
Total current assets	<u>34,211,752</u>	<u>35,613,219</u>
Non-current assets:		
Assets limited as to use, net	48,966,978	44,209,239
Gifts and pledges receivable, net	10,243,507	11,604,982
Prepaid expenses and other assets	255,506	220,911
Due from affiliates	1,175,369	1,061,563
Total non-current assets	<u>60,641,360</u>	<u>57,096,695</u>
Total assets	<u>\$ 94,853,112</u>	<u>\$ 92,709,914</u>
LIABILITIES AND NET POSITION		
Current liabilities:		
Accounts payable and accrued expenses	\$ 484,620	\$ 428,377
Due to affiliate	11,151,782	10,788,987
Total current liabilities	<u>11,636,402</u>	<u>11,217,364</u>
Annuities payable	1,360,196	1,395,360
Total liabilities	<u>12,996,598</u>	<u>12,612,724</u>
Net position:		
Restricted expendable	39,541,797	40,136,216
Restricted non-expendable	31,802,512	31,148,388
Unrestricted	10,512,205	8,812,586
Total net position	<u>81,856,514</u>	<u>80,097,190</u>
Total liabilities and net position	<u>\$ 94,853,112</u>	<u>\$ 92,709,914</u>

See accompanying notes.

ROSWELL PARK CANCER INSTITUTE CORPORATION

STATEMENTS OF REVENUES, EXPENSES AND
CHANGES IN NET POSITION - COMPONENT UNIT
For the Years Ended March 31,

	Roswell Park Alliance Foundation, Inc.	
	<u>2014</u>	<u>2013</u>
Operating revenues:		
Contributions	\$ 18,902,288	\$ 18,904,251
Other operating revenue	563,474	455,990
Total operating revenues	<u>19,465,762</u>	<u>19,360,241</u>
Operating expenses:		
Supplies and other services	1,501,148	1,485,527
Grants	17,757,646	8,888,300
Fundraising	3,977,249	3,702,759
Total operating expenses	<u>23,236,043</u>	<u>14,076,586</u>
(Loss) income from operations	(3,770,281)	5,283,655
Nonoperating revenues:		
Interest and other income	1,069,206	1,088,577
Investment income	4,460,399	2,697,854
Total nonoperating revenues	<u>5,529,605</u>	<u>3,786,431</u>
Excess of revenues over expenses	1,759,324	9,070,086
Net position, beginning of year	<u>80,097,190</u>	<u>71,027,104</u>
Net position, end of year	<u>\$ 81,856,514</u>	<u>\$ 80,097,190</u>

See accompanying notes.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION

Roswell Park Cancer Institute Corporation (the "Institute" or "RPCI") is a public hospital and medical research center located in Buffalo, New York. The Institute is one of only 41 National Cancer Institute-designated comprehensive cancer centers nationwide, providing total care to cancer patients, conducting research into the causes, treatment and prevention of cancer, and educating those who treat and study cancer. The Institute has 133 certified beds.

The Roswell Park Cancer Institute Clinical Practice Plan (the "Plan") was established for the management, including collection and disbursement, of clinical practice income resulting from the clinical practice of licensed health professionals employed by the Institute.

RPCI Oncology, PC ("RPCIO") was established in July 2012 to provide medical oncology and hematology outpatient services. In December 2012, RPCIO acquired Jamestown Medical Oncology Hematology, LLC through an asset purchase agreement for total consideration of approximately \$1,400,000. RPCIO retained control of the operations and assets of the physician practice. The transaction was recorded on RPCIC's consolidated financial statements using the acquisition method of accounting. The acquired assets included working capital, goodwill, a non-compete agreement, and patient medical records.

Carlton & Michigan, LLC ("C&M") was established in May 2013 to construct and operate a new Clinical Science Center ("CSC") that is currently being constructed adjacent to the Institute. C&M, a limited liability company and a pass-through entity for tax purposes, is jointly owned by the Corporation (90%) and the Roswell Park Alliance Foundation (10%), both of which are members in C&M pursuant to an operating agreement signed by and between the parties.

C&M was established to facilitate the financing of the construction of the CSC, part of which is being provided through use of certain New Market Tax Credits ("NMTC"). Refer to Note 7 for further details on the financing of the CSC, including a description of the NMTC program.

Effective January 1, 1999, the Institute became a public benefit corporation of the State of New York ("NYS"), operating under enabling legislation enacted under Title 4 of the Public Authorities Law. The Institute is owned by the State of New York and operated as a public benefit corporation and as such, is a component unit of NYS. Prior to January 1, 1999, the Institute was a division of the New York State Department of Health ("NYSDOH"). As a public benefit corporation, the Institute continues to adhere to the NYS public employees' collective bargaining agreements and is required to provide employee benefits consistent with the NYS Executive Branch.

Discretely Presented Component Unit: U.S. GAAP (as defined in Note 2) requires the inclusion within the Institute's financial statements of Roswell Park Alliance Foundation, Inc. (the "Foundation") as a component unit based on the nature and significance of the Institute's relationship with the Foundation. The component unit information in the accompanying consolidated financial statements includes the financial data of the Institute's discretely presented component unit. The Foundation is reported separately to emphasize that they are legally separate from the Institute.

The Foundation is a not-for-profit corporation organized to receive and administer gifts and bequests made on behalf of the Institute. The Institute utilizes these gifts and bequests in scientific and medical research, for the delivery of medical care to individuals suffering from cancer, and related charitable activities. Scientific and research grants made by the Foundation for use by the Institute are typically paid to and administered by Health Research, Inc. See Note 13 for further information. The financial statements of the Foundation have been prepared on an accrual basis. The annual financial report can be obtained by writing to: Roswell Park Alliance Foundation, Inc., Elm and Carlton Streets, Buffalo, New York 14263.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied in preparing the accompanying consolidated financial statements are summarized below:

Reporting Entity: RPCI, the Plan, RPCIO and C&M (collectively referred to hereinafter as "RPCIC" or the "Corporation") are consolidated for financial statement purposes in accordance with the principles of consolidation in which it is appropriate to consolidate the financial statements of entities under common management and/or control. Collectively, the Institute and the Plan are referred to as the "Public Benefit Corporation" or the "PBC".

Consolidating and combining financial information related to the Institute, the Plan, C&M and RPCIO is included within the supplementary financial information on pages 43 through 46. All significant intercompany balances and transactions have been eliminated in consolidation.

Accounting Principles: RPCIC uses the proprietary fund method of accounting whereby revenues and expenses are recognized on the accrual basis.

For financial accounting and reporting purposes, the Corporation follows all pronouncements of the Governmental Accounting Standards Board ("GASB"), as well as the pronouncements of the Financial Accounting Standards Board ("FASB"), including those FASB pronouncements issued after November 30, 1989 that do not conflict with or contradict GASB pronouncements.

All references to relevant authoritative literature issued by either the GASB or the FASB with which the Corporation must comply are hereinafter referred to generally as "U.S. GAAP."

GASB issued new pension accounting and reporting standards that will result in significant changes for governmental defined benefit pension plans and the employers participating in them. GASB *Statement No. 68, Accounting and Financial Reporting for Pensions—an amendment of GASB Statement No. 27*, ("GASB 68") establishes new financial reporting requirements for most governments that provide their employees with pension benefits through these types of plans. GASB 68 is effective fiscal years beginning after June 15, 2014, with early application encouraged.

Under GASB 68, employers would be required to recognize in their statements of net position the obligation associated with the pension benefits promised to their employees, regardless of the type of benefit plan arrangement used. Governmental healthcare entities participating in multi-employer cost-sharing plans will be required to report a liability equivalent to their proportionate share of the collective unfunded pension obligation of the plan. Each cost-sharing employer will also be required to recognize its estimated allocated share of the plan's collective pension expense.

GASB 68 will significantly change the accounting and financial reporting of such multi-employer pension plans. Consequently, upon adoption of GASB 68, the Institute will be required to recognize in its financial statements its' allocation of the difference between the actuarially calculated liability and the funded position of that portion of the plan. As such, the Corporation will recognize a liability if the plan is underfunded or an asset if the plan is overfunded. Currently there is insufficient information available to determine the effects of adoption of GASB 68.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

GASB Concepts *Statement No. 4, Elements of Financial Statements*, specifies that recognition of deferred outflows of resources and deferred inflows of resources should be limited to those instances specifically identified in authoritative GASB pronouncements. Consequently, guidance was needed to determine which balances being reported as assets and liabilities should actually be reported as deferred outflows of resources or deferred inflows of resources, according to the definitions in GASB Concepts *Statement No. 4*. Based on those definitions, GASB *Statement No. 65, Items Previously Reported as Assets and Liabilities*, reclassifies certain items currently being reported as assets and liabilities as deferred outflows of resources and deferred inflows of resources. In addition, this statement recognizes certain items currently being reported as assets and liabilities as outflows of resources and inflows of resources. This statement also provides financial reporting guidance related to the impact of the financial statement elements' deferred outflows of resources and deferred inflows of resources, such as changes in the determination of the major fund calculations and limiting the use of the term *deferred* in financial statement presentations.

During the year ended March 31, 2014 the Corporation adopted GASB 65, which resulted in a write-off of certain costs previously reported as deferred financing costs. An adjustment of \$5,005,635 was recorded as a decrease to net position for the period beginning April 1, 2012 in the consolidated statement of net position and statement of revenues, expenses and changes in net position.

The adoption of the new pronouncement has been accounted for retrospectively and as such, certain 2013 figures have been restated as depicted below.

	<u>Previously Stated 2013</u>	<u>Adjustment 2013</u>	<u>Restated 2013</u>
Beginning net position	\$ 146,883,968	\$ (5,005,635)	\$ 141,878,333
Deferred financing costs	\$ 4,576,294	\$ (4,576,294)	\$ -
Depreciation and amortization expense	\$ 35,778,053	\$ (429,341)	\$ 35,348,712

As of June 30, 2009, the GASB has codified all sources of authoritative accounting literature pertaining to state and local government entities into a single set of authoritative literature, known as the GASB Codification. The GASB Codification includes all authoritative GASB pronouncements issued and effective as of June 30, 2009. Updates to the GASB Codification will be made from time to time as determined by the GASB pursuant to the GASB's rule-making protocols and procedures. These updates may alter, amend, supplement, revoke or supersede the guidance contained in the GASB Codification as of the date of this report.

Similarly, effective for interim and annual periods ending after September 15, 2009, the Financial Accounting Standards Board ("FASB") has codified all sources of authoritative accounting literature pertaining to all non-governmental entities into a single set of authoritative literature, known as the FASB Accounting Standards Codification ("FASC"). The FASC includes all authoritative literature previously issued by recognized standard-setting bodies pertaining to accounting principles generally accepted in the United States; thereby superseding all previously issued authoritative pronouncements relating to non-governmental entities.

Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Significant estimates made by RPCIC include, but are not limited to, reserves for bad debts and third-party payor contractual adjustments and allowances, workers' compensation and malpractice reserves, post employment benefit accruals and the fair value of investments. Actual results could differ from those estimates.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Risks and Uncertainties: Investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is at least possible that changes in risks in the near term could materially affect the net position of RPCIC.

Cash and Cash Equivalents: RPCIC considers all highly liquid investments, with original maturities of three months or less, and short term investments (certificates of deposit), excluding amounts limited as to use, to be cash equivalents. RPCIC maintains funds on deposit in excess of amounts insured by the Federal Depository Insurance limits. In accordance with its investment policies and the NYS Comptroller's Investment Guidelines for Public Authorities, RPCIC maintains collateral accounts with certain financial institutions to limit RPCIC's exposure associated with Federal Depository Insurance limits.

Inventory Valuation: Inventories are stated at the lower of average cost or market on a first-in, first-out basis.

Assets Limited as to Use: Assets limited as to use include assets set aside for debt service as required by trustee or indenture agreements, assets held under the Plan enabling legislation, assets set aside pursuant to donor stipulations, and assets designated by the Board of Directors for specific future purposes. If donated or contributed, assets limited as to use are reported at fair value as of the date of receipt, which is then treated as cost. Interest income on proceeds of borrowings that are held by a Trustee, and principally all other general fund investments, are reported as interest and other income. Classification in the consolidated statement of net position between current and non-current is generally determined by the purpose for which the assets are set aside.

Capital Assets: Capital assets are stated at historical cost. Depreciation is provided on the straight-line method over the useful lives of the assets ranging from 3 to 40 years, which are primarily determined based on the American Hospital Association's Guidelines. For certain buildings and equipment previously acquired or constructed, RPCIC assigned composite lives which it believes will more appropriately reflect its financial results by better allocating costs relating to the major modernization project over the useful lives of the related assets. Amortization of equipment under capital leases is provided on the straight-line method over the term of the lease or the useful lives of the assets.

Impairment of Long-Lived Assets: Under the provisions of Statement of Governmental Accounting Standards Board No. 42, *Accounting and Financial Reporting for Impairment of Capital Assets and for Insurance Recoveries*, RPCIC evaluates its capital assets for financial impairment as prominent events or changes in circumstances affecting capital assets occur to determine whatever impairment of a capital asset has occurred. No adjustments were made in 2014 and 2013 as a result of performing these evaluations.

Net Position: Net position is classified into categories according to external donor restrictions or availability of assets to satisfy RPCIC's obligations, as discussed below.

Net investment in capital assets consists of capital assets, including restricted capital assets, reduced by accumulated depreciation and by any outstanding debt incurred to acquire, construct, or improve those assets.

Restricted expendable net position represents the net position with limits on their use that are externally imposed (by creditors, grantors, contributors, or laws and regulations) or that are imposed by RPCIC's Board of Directors which are not required to be retained in perpetuity.

Unrestricted net position consists of net position that does not meet the definition of any of the other two components.

Noncontrolling interest consists of the percentage of C&M's net position not controlled by the Institute. The change in net position attributable to noncontrolling interest for the year ended March 31, 2014 was \$2,280 (\$0 – 2013).

Social Accountability: RPCIC has a policy to provide financial assistance in the form of discounts from medical charges for patients who have been determined by RPCIC to need treatment at RPCIC and who do not have the ability to pay full charges, as determined under the qualifications criteria set forth in the aforementioned policy.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The allowances for estimated uncollectibles for patient accounts receivable include accounts referred to the NYS Attorney General for collection.

Net Patient Service Revenue: Net patient service revenue and patient accounts receivable are recorded at the estimated net realizable amounts from patients, third-party payors, and others for services rendered including estimated adjustments under various reimbursement agreements with third-party payors. Third-party payors retain the right to review and propose adjustments to amounts recorded by RPCIC. Such adjustments are accrued, when deemed probable and estimable; in the period the related services are rendered and adjusted in future periods as final settlements are determined. Management believes that adequate provision has been made in the consolidated financial statements for any adjustments that may result from final settlements. The impact of recording final settlements, pool payments and other third party payor adjustments resulted in the recognition of additional net operating revenues of approximately \$16,122,590 and \$21,663,774, in 2014 and 2013, respectively.

Inpatient services rendered to Medicare program beneficiaries are based on a cost reimbursement methodology subject to certain ceilings for inpatient services. RPCIC is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by RPCIC and audits thereof by the Medicare fiscal intermediary.

Under the New York Health Care Reform Act ("NYHCRA"), hospitals are authorized to negotiate reimbursement rates with certain non-Medicare payors except for Medicaid, Workers' Compensation and No-fault, which are regulated by NYS. These negotiated rates may take the form of rates per discharge, reimbursed costs, and discounted charges or as per diem payments. Reimbursement rates for non-Medicare payors regulated by NYS are determined on a prospective basis. These rates also vary according to a patient classification system defined by NYHCRA that is based on clinical, diagnostic and other factors.

Outpatient services are paid under various reimbursement methodologies, including prospectively determined rates, cost reimbursement, fee schedules, and charges.

Approximately 17% and 20% of net patient service revenue was generated from the combined services rendered to patients under Medicare and Medicaid programs in 2014 and 2013, respectively. Approximately 65% and 64% of net patient service revenue was generated from the combined services rendered to patients under managed care programs in 2014 and 2013, respectively.

Net patient service revenue, as reported on the consolidated statement of revenues, expenses and changes in net position is comprised of the following for the years ended March 31:

	<u>2014</u>	<u>2013</u>
Gross charges	\$ 1,040,946,641	\$ 987,551,995
Less:		
Discounts and allowances	(612,586,959)	(582,600,851)
Provision for bad debts	<u>(5,252,043)</u>	<u>(5,793,408)</u>
	<u>\$ 423,107,639</u>	<u>\$ 399,157,736</u>

Other Operating Revenue: RPCIC considers revenues received from the operation of the cafeteria, the parking garage and other ancillary activities as operating revenue.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The composition of other operating revenue is as follows for the years ended March 31:

	<u>2014</u>	<u>2013</u>
Cafeteria	\$ 1,750,668	\$ 1,723,452
Parking garage	2,284,824	2,074,437
Rebates	1,388,227	827,662
Rental income	1,328,949	1,172,107
Other	<u>3,486,949</u>	<u>3,648,702</u>
	<u>\$ 10,239,617</u>	<u>\$ 9,446,360</u>

Grants and Contracts: As more fully described in Note 13, grants and contracts consist of amounts paid to RPCIC by a related party, primarily for the recruitment and retention of certain medical and research staff.

Non-operating Revenues (Expenses): Interest and other income and investment loss, consist primarily of interest income and earnings (losses) on assets limited as to use, less amounts charged by the Dormitory Authority of the State of New York ("DASNY") for administrative services associated with RPCIC's indebtedness, see Note 7.

Deficiency of Revenues over Expenses: The consolidated statement of revenues, expenses and changes in net position includes "deficiency of revenues over expenses." Changes in unrestricted net position which is excluded from deficiency of revenues over expenses include grants and contributions for the purchase of capital assets.

Contributions for Purchase of Capital Assets: Contributions for purchase of capital assets consist principally of amounts received under the HEAL NY program, as well as amounts transferred between RPCIC, Health Research, Inc. ("HRI"), the Foundation and the Empire State Development Corporation ("ESD"), all of which are related parties. Contributions from the Foundation for the Clinical Sciences Center, discussed below, were \$7,850,752 and \$0 in 2014 and 2013, respectively, and were for the purchase of capital assets. ESD also contributed \$2,550,000 and \$0 for other capital assets in 2014 and 2013, respectively. Contributions from HRI approximated \$1,728,123 and \$2,113,834 in 2014 and 2013, respectively, and were for the purchase of other capital assets.

The contributions from the Foundation consist principally of the recognition of pledged support from the Foundation related to the construction of the Clinical Sciences Center. In accordance with GASB Statement No. 33, *Accounting and Financial Reporting for Non-Exchange Transactions*, RPCIC is recognizing such pledged support as a voluntary non-exchange transaction. As such, contribution revenue from the Foundation is recognized concurrently, in timing and amount, with the progress of the construction of the Clinical Sciences Center, to the extent donor resources are deemed available as defined by GASB No. 33.

Taxes: As a public benefit corporation the Institute and the Plan are exempt from federal and state income taxes under Section 115 of the Internal Revenue Code, as well as state and local property and sales taxes. As such, no provision for income taxes is made by either the Institute or the Plan.

RPCIO was formed as a taxable corporation under the laws of NYS and an application to the IRS for tax exempt status is pending approval as of the date these financial statements were available to be released. Accordingly, management has analyzed and prepared a calculation for income tax purposes to assess the income tax liability or benefit resulting from RPCIO's activities for the year ended March 31, 2014 and 2013. For the year ended March 31, 2014 and 2013, RPCIO's activities resulted in a net operating loss and the recognition of a deferred tax asset ("DTA") relating thereto. In addition, RPCIC recorded a full valuation allowance against the DTA as management does not believe they will be able to realize the DTA in the future.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

C&M operates as a limited liability company and is taxed as a partnership under the terms of the operating agreement.

Reclassifications: Certain prior year amounts were reclassified to conform to the 2014 consolidated financial statement presentation.

Subsequent Events: These consolidated financial statements have not been updated for subsequent events occurring after June 13, 2014 which is the date these consolidated financial statements were available to be issued.

NOTE 3. ASSETS LIMITED AS TO USE

Assets limited as to use consisted of the following at March 31:

	<u>2014</u>	<u>2013</u>
Board Designated (a)		
Board designated funds for recruitment, capital and accruals	\$ 94,238,937	\$ 97,845,080
Board designated funds for strategic investment	10,000,000	10,000,000
Board designated funds for unfunded future retirement obligations and other strategic initiatives	54,358,722	-
Board designated funds for construction projects	17,162,171	-
Workers compensation	8,846,031	7,513,678
Employee benefits	2,302,682	2,274,746
Estimated third party settlements/unearned revenue	1,833,329	2,652,000
Technology transfer	1,000,000	1,000,000
TIAA/CREF escrow	282,945	299,931
	<u>190,024,817</u>	<u>121,585,435</u>
Held by Trustee Under Malpractice and General Liability Trust Agreement		
Malpractice reserve:		
Cash and cash equivalents	91,397	600,496
U.S. Government obligations	13,303,672	12,797,653
	<u>13,395,069</u>	<u>13,398,149</u>
Held by Trustee Under Indenture Agreement (b)		
Debt service reserve	27,909,376	37,980,318
Major modernization project	17,686,667	17,594,750
Other	10,000	10,000
	<u>45,606,043</u>	<u>55,585,068</u>
Held under Clinical Practice Plan Enabling Legislation (c)		
Chief Executive Officer fund	10,258,588	8,922,999
Academic development fund - Chief Executive Officer	12,773,306	13,104,798
Academic development fund – Department Chairperson	5,854,035	7,294,481
	<u>28,885,929</u>	<u>29,322,278</u>
	277,911,858	219,890,930
Less: Current portion	<u>(51,190,610)</u>	<u>(38,557,307)</u>
	<u>\$ 226,721,248</u>	<u>\$ 181,333,623</u>

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3. ASSETS LIMITED AS TO USE (CONTINUED)

- (a) the Board Designated funds are all invested in cash and cash equivalents.
- (b) the assets held by Trustee under Indenture agreement are all invested in cash and cash equivalents.
- (c) the Clinical Practice Plan funds that are held under enabling legislation are all invested in cash and cash equivalents.

The current portion of assets limited as to use is determined based on the anticipated timing of use of the funds.

NOTE 4. CAPITAL ASSETS

	<u>March 31, 2013</u>	<u>Additions</u>	<u>Deductions</u>	<u>March 31, 2014</u>
Non-depreciable assets:				
Land	\$ 4,291,887	\$ -	\$ -	\$ 4,291,887
Construction in progress	<u>16,082,559</u>	<u>33,079,766</u>	<u>(8,112,174)</u>	<u>41,050,151</u>
	20,374,446	33,079,766	(8,112,174)	45,342,038
Depreciable assets:				
Buildings and improvements	499,741,151	4,854,841	(335,789)	504,260,203
Equipment	<u>189,072,395</u>	<u>11,314,909</u>	<u>(5,795,452)</u>	<u>194,591,852</u>
	688,813,546	16,169,750	(6,131,241)	698,852,055
Less: Accumulated depreciation:				
Buildings and improvements	279,688,223	18,170,613	-	297,858,836
Equipment	<u>137,872,788</u>	<u>16,665,400</u>	<u>(5,739,601)</u>	<u>148,798,587</u>
	<u>417,561,011</u>	<u>34,836,013</u>	<u>(5,739,601)</u>	<u>446,657,423</u>
Capital assets, net	<u>\$ 291,626,981</u>	<u>\$ 14,413,503</u>	<u>\$ (8,503,814)</u>	<u>\$ 297,536,670</u>
	<u>March 31, 2012</u>	<u>Additions</u>	<u>Deductions</u>	<u>March 31, 2013</u>
Non-depreciable assets:				
Land	\$ 4,291,887	\$ -	\$ -	\$ 4,291,887
Construction in progress	<u>7,046,309</u>	<u>18,713,720</u>	<u>(9,677,470)</u>	<u>16,082,559</u>
	11,338,196	18,713,720	(9,677,470)	20,374,446
Depreciable assets:				
Buildings and improvements	492,488,325	7,252,826	-	499,741,151
Equipment	<u>170,020,812</u>	<u>21,511,061</u>	<u>(2,459,478)</u>	<u>189,072,395</u>
	662,509,137	28,763,887	(2,459,478)	688,813,546
Less: Accumulated depreciation:				
Buildings and improvements	259,316,625	20,371,598	-	279,688,223
Equipment	<u>125,348,788</u>	<u>14,949,328</u>	<u>(2,425,328)</u>	<u>137,872,788</u>
	<u>384,665,413</u>	<u>35,320,926</u>	<u>(2,425,328)</u>	<u>417,561,011</u>
Capital assets, net	<u>\$ 289,181,920</u>	<u>\$ 12,156,681</u>	<u>\$ (9,711,620)</u>	<u>\$ 291,626,981</u>

Depreciation expense amounted to approximately \$34,836,000 and \$35,321,000 in 2014 and 2013, respectively.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5. ACCRUED EXPENSES

The disaggregated components of accrued expenses are as follows at March 31:

	<u>2014</u>	<u>2013</u>
Salaries and benefits	\$ 34,799,785	\$ 34,833,669
Payroll withholdings	4,284,635	4,494,958
Current portion of retirement and post-retirement benefits	6,497,912	6,010,224
Workers compensation	8,846,031	7,513,678
Professional and general liability	23,660,043	18,631,628
Accrued interest	2,470,202	2,599,216
Other	<u>1,919,286</u>	<u>3,018,838</u>
	<u>\$ 82,477,894</u>	<u>\$ 77,102,211</u>

NOTE 6. SHORT-TERM BORROWINGS

On November 29, 2012, RPCIC signed an agreement with M&T Bank, which allows for borrowings up to \$25,000,000. Borrowings bear interest at one month LIBOR, adjusted daily, plus 140 basis points (1.60% as of March 31, 2014). There was no balance outstanding under this agreement as of March 31, 2014 and 2013. This agreement was entered into primarily to provide borrowing authority in the event NYS support payments are delayed on a short-term basis. The agreement substitutes a previous agreement with HSBC Bank, USA, which has been terminated upon the establishment of the M&T Bank agreement.

On April 25, 2012, RPCIC entered into a Delayed Draw Term Loan for \$15,000,000 with M&T Bank in connection with the construction of the Clinical Science Center. There was no balance outstanding under this agreement as of March 31, 2014 and 2013. This Term Loan was entered into to provide a short-term bridge funding source that is intended to fund the timing difference between donor pledge payments and Clinical Science Center construction costs.

NOTE 7. LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS

The long-term debt obligations of RPCIC consist primarily of allocated portions of DASNY bonds issued on behalf of RPCIC and certain other NYSDOH facilities. The portion of these obligations allocated to RPCIC was derived from budgeted construction costs and is subject to periodic change based on actual costs incurred. All bonds are collateralized by a first lien on the revenues of RPCIC.

As of March 31, long-term debt consists of the following:

	<u>2014</u>	<u>2013</u>
On December 4, 2003, DASNY issued debt in the amount of \$41,910,000 (RPCIC allocated 85.00%). Under the terms of issuance, interest ranges from 2.0% to 5.25% per annum with interest and principal payments due through 2024. The bond proceeds were used solely to defease a portion of the outstanding 1994, 1995 and 1996 bond series.	\$ 22,928,750	\$ 24,871,000
On April 7, 2004, DASNY issued debt in the amount of \$77,245,000 (RPCIC allocated 95.15%). Under the terms of issuance, interest ranges from 2.0% to 5.0% per annum with interest and principal payments due through 2024. The bond proceeds were used solely to defease a portion of the outstanding 1994, 1995 and 1996 bond series.	27,417,470	36,004,760

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7. LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS (CONTINUED)

	<u>2014</u>	<u>2013</u>
On April 7, 2004, DASNY issued debt in the amount of \$78,870,000 (RPCIC allocated 95.51%). Under the terms of issuance, interest ranges from 2.0% to 5.0% per annum with interest and principal payments due through 2023. The bond proceeds were used solely to defease a portion of the outstanding 1994, 1995 and 1996 bond series.	64,249,577	64,378,516
On May 24, 2005, DASNY issued debt in the amount of \$51,465,000 (RPCIC allocated 95.51%). Under the terms of issuance, interest ranges from 3.0% to 5.25% per annum with interest and principal payments due through 2026. The bond proceeds were used solely to defease a portion of the outstanding 1996 bond series.	47,950,796	48,017,652
On July 13, 2011, DASNY issued debt in the amount of \$48,180,000 (RPCIC allocated 74.85%). Under the terms of issuance, interest ranges from 2.0% to 5.0% per annum with interest and principal payments due through 2024. The bond proceeds were used solely to defease a portion of the outstanding 1998 bond series.	33,068,730	34,591,927
C&M loans payable under NMTC program (a).	29,780,000	-
On June 1, 2012, RPCIC entered into a capital lease obligation to rent 226 parking spaces for a 35 year period. Under terms of the agreement, the cost of capital is estimated at 3.4% per annum with interest and principal payments due through 2047.	4,532,317	4,522,957
	<u>229,927,640</u>	<u>212,386,812</u>
Plus: Unamortized bond premium	<u>6,966,276</u>	<u>8,375,433</u>
Total long-term obligations	236,893,916	220,762,245
Less: Current portion	<u>(12,858,331)</u>	<u>(12,248,532)</u>
Long-term obligations, net	<u>\$ 224,035,585</u>	<u>\$ 208,513,713</u>

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7. LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS (CONTINUED)

<u>Obligation Type</u>	<u>March 31, 2013</u>	<u>Additions</u>	<u>Deductions</u>	<u>March 31, 2014</u>
Bond Series 2003	\$ 24,871,000	\$ -	\$ 1,942,250	\$ 22,928,750
Bond Series 2004	36,004,760	-	8,587,290	27,417,470
Bond Series 2004	64,378,516	-	128,939	64,249,577
Bond Series 2005	48,017,652	-	66,856	47,950,796
Bond Series 2011	34,591,927	-	1,523,197	33,068,730
Loans payable	-	29,780,000	-	29,780,000
Capital lease	<u>4,522,957</u>	<u>9,360</u>	<u>-</u>	<u>4,532,317</u>
	212,386,812	29,789,360	12,248,532	229,927,640
Plus: Unamortized bond premium	<u>8,375,433</u>	<u>-</u>	<u>1,409,157</u>	<u>6,966,276</u>
Total long-term obligations	220,762,245	<u>\$ 29,789,360</u>	<u>\$ 13,657,689</u>	236,893,916
Less: Current portion	<u>(12,248,532)</u>			<u>(12,858,331)</u>
Long-term obligations, net	<u>\$ 208,513,713</u>			<u>\$ 224,035,585</u>

<u>Obligation Type</u>	<u>March 31, 2012</u>	<u>Additions</u>	<u>Deductions</u>	<u>March 31, 2013</u>
Bond Series 2003	\$ 26,728,250	\$ -	\$ 1,857,250	\$ 24,871,000
Bond Series 2004	44,192,417	-	8,187,657	36,004,760
Bond Series 2004	64,502,679	-	124,163	64,378,516
Bond Series 2005	48,079,734	-	62,082	48,017,652
Bond Series 2011	36,062,730	-	1,470,803	34,591,927
Capital lease	<u>-</u>	<u>4,522,957</u>	<u>-</u>	<u>4,522,957</u>
	219,565,810	4,522,957	11,701,955	212,386,812
Plus: Unamortized bond premium	<u>9,907,614</u>	<u>-</u>	<u>1,532,181</u>	<u>8,375,433</u>
Total long-term obligations	229,473,424	<u>\$ 4,522,957</u>	<u>\$ 13,234,136</u>	220,762,245
Less: Current portion	<u>(11,701,955)</u>			<u>(12,248,532)</u>
Long-term obligations, net	<u>\$ 217,771,469</u>			<u>\$ 208,513,713</u>

(a) As discussed in Note 1, the Institute, C&M and the Foundation are all parties to a series of transactions entered into to finance the construction of the CSC. By consummating these transactions, the Institute will be able to garner the benefit of certain New Market Tax Credit ("NMTC") enhanced financing to partially fund the construction of the CSC. The NMTC program was established pursuant to federal legislation in the year 2000 and is administered through the CDFI Fund of the United States Department of the Treasury. The purpose of the NMTC program is to provide an incentive for businesses to invest in projects being built or operated in low income communities. To be considered eligible, various criteria must be met pertaining to the project itself (in this case, the construction and operation of the CSC), as well as the participating entities themselves (in this case, the Institute, C&M, the Foundation and certain other unrelated investor entities). Further information on the New Market Tax Credit program can be found at www.cdifund.gov.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7. LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS (CONTINUED)

Under the program, participating NMTC investors will receive a maximum 39% tax credit over a period of seven years on qualified equity investments totaling approximately \$30.5 million made in the construction of the CSC. Through its participation in the NMTC program, RPCIC expects to recognize a net benefit from the program of approximately \$6.2 million, which represents the NMTC investors' equity investment in the tax credits less all fees and expenses.

Pursuant to the laws and regulations surrounding the NMTC program, several entities are party to the overall financing plan. RPCIC leveraged its own funds (both internal equity and funds raised by the Foundation through a capital campaign), a portion of which were loaned to two unrelated NMTC investment funds. These NMTC investment funds then made qualifying equity contributions into various Community Development Entities ("CDEs"), which in turn loaned those funds as qualified low-income community investments to C&M to fund the construction of the CSC. The following recaps the amounts recognized in the consolidated statement of net position as of March 31, 2014:

	Asset (Liability)
Notes Receivable: RPCIC funds loaned to NMTC investment funds	\$ 21,260,833
Notes Payable: Amounts borrowed by C&M from CDEs to fund construction of the CSC	\$ (29,780,000)

The NMTC program requires the financing structure to remain in place for a period of not less than seven (7) years from the date in which the NMTC investment funds make the qualified equity investment into the CDEs (the "Compliance Period"). During the Compliance Period, C&M makes interest-only payments on the loans from the CDEs. The CDEs use the interest payments to pay fees and distribute the remaining proceeds to the NMTC Investment Funds. The NMTC investment funds then use the proceeds to make interest-only payments on their notes payable to RPCIC. At the conclusion of the Compliance Period, the investors in the NMTC investment funds have the option to have their interest in the CDEs redeemed, which will result in the CDEs assigning their assets to the NMTC investment funds, including the Notes Receivable from C&M. Additionally, the NMTC Investors have the option to put their interest in the NMTC investment funds to RPCIC for a price of \$1,000. If the NMTC Investors do not exercise their put options, RPCIC may exercise a call option to purchase the NMTC Investors' interests in the NMTC investment funds for a price equal to the fair market value of the interests. Exercise of either the put or call options will effectively transfer ownership of the NMTC investment funds to RPCIC, which will allow RPCIC to cancel the loans between the NMTC investment funds and C&M. Recognition of the estimated \$6.2 million NMTC net benefit, represented as the difference in value of the NMTC investment interests and the loans payable to the CDEs at the end of the Compliance Period, is contingent upon the exercise of either the put or call options, and thus is considered a gain contingency. Recognition of the NMTC benefit is therefore deferred until such time as the put or call options are exercised, which is expected to be no sooner than the expiration of the Compliance Period in September, 2020.

In connection with certain of these financing arrangements, RPCIC previously recognized its portion of the premiums and debt issuance costs related to each issue. As discussed in Note 1, due to the adoption of GASB 65 net assets were restated for the write off of deferred issuance costs. RPCIC uses the effective interest method for amortizing these premiums. Included as an offset to interest expense is \$1,409,157 and \$1,532,181 in 2014 and 2013, respectively, related to the amortization of bond premium.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7. LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS (CONTINUED)

Future principal and interest payments on long-term debt are summarized as follows:

Year ending March 31,	Long-term debt		Capital lease	
	<u>Principal</u>	<u>Interest</u>	<u>Principal</u>	<u>Interest</u>
2015	\$ 12,858,331	\$ 9,756,328	\$ (5,276)	\$ 154,193
2016	13,278,850	9,103,691	(921)	154,307
2017	13,055,128	8,437,044	3,722	154,267
2018	13,726,109	7,745,645	8,663	154,064
2019	15,688,776	6,999,065	13,920	153,689
2020 – 2024	97,521,986	28,702,652	160,593	755,962
2025 – 2030	41,986,998	2,969,315	348,854	713,684
Thereafter	<u>17,279,145</u>	<u>1,146,502</u>	<u>4,002,762</u>	<u>1,526,194</u>
	225,395,323	74,860,242	4,532,317	3,766,360
Plus: Unamortized bond premium	<u>6,966,276</u>	-	-	-
	<u>\$ 232,361,599</u>	<u>\$ 74,860,242</u>	<u>\$ 4,532,317</u>	<u>\$ 3,766,360</u>

NOTE 8. POSTEMPLOYMENT BENEFITS

Benefit Plan Description: Employees of RPCIC participate in the New York State Health Insurance Plan (the “Benefit Plan”), a defined benefit, agent multiple employer-type plan administered by the NYS Department of Civil Service Employee Benefits Division. The Benefit Plan offers a range of benefits to its participants, including inpatient, outpatient and emergency services, as well as mental health coverage and prescription drug benefits. The Benefit Plan offers benefits through the New York State Health Insurance Empire Plan and two Health Maintenance Organizations (“HMO’s”), each of which contain varying levels of coverage and cost. The Benefit Plan does not issue a stand-alone report.

Funding Policy: RPCIC has the authority to establish its own funding policy. Under its current policy, RPCIC is not required to fund the Benefit Plan or the Annual Required Contribution (“ARC”, an actuarial determined amount as defined by U.S. GAAP). RPCIC is seeking relief from NYS for all or a significant portion of the unfunded OPEB liability. To date, NYS has not agreed to this relief.

The Benefit Plan requires participants to contribute a portion of the monthly premiums. The following table illustrates the participant contribution rates per plan for 2014 and 2013.

<u>Plan</u>	<u>Tier</u>	<u>Participant Contribution</u>	
		<u>2014</u>	<u>2013</u>
Empire Plan	Single	60.96	56.30
	Family	276.33	251.87
Community Blue	Single	62.70	62.10
	Family	330.21	342.94
Independent Health	Single	67.64	92.56
	Family	278.98	339.89

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8. POSTEMPLOYMENT BENEFITS (CONTINUED)

Annual Other Postemployment Benefit Cost and Net Other Postemployment Benefit Obligation (OPEB): RPCIC's annual OPEB cost is calculated based on the ARC of the employer. The ARC represents a level of funding that, if paid on an ongoing basis, is projected to cover normal cost each year and amortize any unfunded actuarial liabilities (or funding excess) over a period not to exceed thirty years. The following table shows the components of RPCIC's annual OPEB cost, the amount actually contributed to the plan, and changes in the net OPEB obligation for 2014 and 2013:

	<u>2014</u>	<u>2013</u>
<u>Annual OPEB Cost</u>		
Annual Required Contribution ("ARC")	\$ 54,048,528	\$ 53,516,149
Interest on Net OPEB Obligation	8,096,825	6,784,113
Adjustment to Annual Required Contribution	<u>(13,769,800)</u>	<u>(11,537,346)</u>
Annual OPEB Cost	<u>\$ 48,375,553</u>	<u>\$ 48,762,916</u>
<u>Net OPEB Obligation</u>		
Net OPEB Obligation – beginning of year	\$ 269,894,159	\$ 226,137,075
Annual OPEB Cost	48,375,553	48,762,916
Employer Contributions	<u>(5,662,489)</u>	<u>(5,005,834)</u>
Net OPEB Obligation – end of year	312,607,223	269,894,157
Less: Current portion	<u>(6,497,913)</u>	<u>(6,010,224)</u>
Long-term OPEB obligation	<u>\$ 306,109,310</u>	<u>\$ 263,883,933</u>

The following table illustrates RPCIC's annual OPEB cost, percentage of annual OPEB cost contributed by RPCIC, and the net OPEB obligation for 2014, 2013 and 2012.

<u>Fiscal Year</u>	<u>Annual OPEB Cost</u>	<u>Percentage of Annual OPEB Cost Contributed</u>	<u>Net OPEB Obligation</u>
3/31/2012	\$ 47,020,290	9.90%	\$ 226,137,075
3/31/2013	\$ 48,762,916	10.27%	\$ 269,894,157
3/31/2014	\$ 48,375,553	11.71%	\$ 312,607,223

Funded Status and Funding Progress: The most recent actuarial valuation for the OPEB plan was as of April 1, 2013. As of March 31, 2014, the plan was unfunded. As discussed on the following page under "Matters Involving New York State", RPCIC is seeking support from NYS to fund all or a significant portion of the unfunded OPEB liability. RPCIC believes it will need some form of assistance from NYS in order to meet future OPEB obligations resulting from the benefits that have, and will continue to, accrue under the Plan. The actuarial accrued liability ("AAL") for benefits was \$587,472,741 and \$485,125,275 in 2014 and 2013, respectively, and the actuarial value of assets was \$0 in 2014 and 2013, resulting in an unfunded actuarial accrued liability ("UAAL") of \$587,472,741 and \$485,125,275 in 2014 and 2013, respectively. The covered payroll (annual payroll of active employees covered by the plan) was \$192,131,062 and \$186,690,252 in 2014 and 2013, respectively, and the ratio of the UAAL to the covered payroll was 305.77% and 259.86% in 2014 and 2013, respectively.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8. POSTEMPLOYMENT BENEFITS (CONTINUED)

Actuarial valuations of an ongoing plan involve estimates of the value of reported amounts and assumptions about the probability of occurrence of events far into the future. Examples include assumptions about future employment, mortality, and the healthcare cost trend. Amounts determined regarding the funded status of the plan and the annual required contributions of the employer are subject to continual revision as actual results are compared with past expectations and new estimates are made about the future. The schedule of funding progress, presented in management's discussion and analysis preceding the notes to the financial statements, presents multiyear trend information about whether the actuarial value of plan assets is increasing or decreasing over time relative to the actuarial accrued liabilities for benefits.

Actuarial Method and Assumptions: Projections of benefits for financial reporting purposes are based on the substantive plan (the plan as understood by the employer and the plan members) and include the types of benefits provided at the time of each valuation and the historical pattern of sharing of benefit costs between the employer and plan members to that point. The actuarial methods and assumptions used include techniques that are designed to reduce the effects of short-term volatility in actuarial accrued liabilities and the actuarial value of assets, consistent with the long-term perspective of the calculations.

In 2014 and 2013 the entry age normal cost method was used. The actuarial assumptions included a 3.0 percent investment rate of return, which is the expected long-term investment returns on the employer's own investments, and an annual healthcare cost trend rate of 8.0 percent, reduced to an ultimate rate of 5.0 percent in 2024. An inflation assumption of 2.5 percent was used in 2014 and 2013. The assumed rate of annual salary increase is 3.5 and 5.0 percent in 2014 and 2013, respectively. The UAAL is being amortized as a level dollar of projected payroll on an open basis. The remaining amortization period at March 31, 2014, was twenty-two years.

Matters Involving New York State: RPCIC has recognized in its consolidated statement of net position and consolidated statement of revenues, expenses and changes in net position the amounts described above. In so doing, RPCIC has assumed that it will be liable for the portion of benefits attributable to services provided by its employees for the period subsequent to January 1, 1999, the date at which RPCIC became a public benefit corporation of the State of New York. As discussed previously, RPCIC is seeking some form of financial assistance from NYS to fund all or a significant portion of the unfunded OPEB liability. RPCIC believes it will need some form of assistance from NYS in order to meet the future OPEB plan obligations resulting from the benefits that have, and will continue to, accrue under the OPEB plan.

If the State of New York were to agree to assume all of the benefits for the time period it operated Roswell Park (e.g. prior to 1/1/99), RPCIC would have the potential to recognize the reduction in its accrued liability for any amounts of that liability to which the State would agree to accept.

The following table illustrates the actuarially-derived estimates of the postemployment benefit liability and associated costs as of March 31, 2014, utilizing a cut-off date of January 1, 1999:

	<u>Prior to January 1, 1999</u>	<u>Post January 1, 1999</u>	<u>Total</u>
Actuarial accrued liability ("AAL")	\$ 141,462,997	\$ 446,009,744	\$ 587,472,741
Annual required contribution ("ARC")	7,066,348	46,982,180	54,048,528
Annual OPEB cost	6,333,489	42,042,064	48,375,553
Net OPEB obligation:			
Net OPEB obligation – beginning of year	34,866,091	235,028,068	269,894,159
Annual OPEB cost	6,333,489	42,042,064	48,375,553
Employer contributions	<u>(3,336,612)</u>	<u>(2,325,877)</u>	<u>(5,662,489)</u>
Net OPEB obligation – end of year	<u>\$ 37,862,968</u>	<u>\$ 274,744,255</u>	<u>\$ 312,607,223</u>

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9. INSURANCE ARRANGEMENTS

RPCIC is exposed to various risks of loss from torts, theft of, damage to, and destruction of assets, business interruption, errors and omissions, employee injuries and illnesses, natural disasters, and employee health, dental and accident benefits. RPCIC's insurance arrangements are as follows:

Professional and General Liability: RPCIC maintains a partially self-insured program covering general and professional liability claims against RPCIC and its employees. RPCIC maintains claims made insurance coverage to cover losses in excess of \$2 million per incident and \$5 million in aggregate per year, including defense costs. In addition, RPCIC purchased excess general and professional liability coverage covering the next \$10 million per claim and \$10 million in the aggregate per year, over and above RPCIC's retained exposure. Professional liability coverage is on a claims made basis, while general liability coverage is occurrence based. Claims alleging malpractice have been asserted against RPCIC and are currently in various stages of litigation. It is the opinion of management that the existing reserves, insurance policies and funds held by a trustee under the malpractice and general liability trust agreement (see Note 3) are adequate to provide for potential losses resulting from pending or threatened litigation of which management is currently aware. Additional claims may have been asserted against RPCIC through March 31, 2014, for which reserves have been estimated. Claim reserves were discounted using a rate of 3% in 2014 and 2013, respectively.

The charges to expenses for medical malpractice costs approximated \$9,870,041 and \$5,656,581 in 2014 and 2013, respectively.

Workers' Compensation: RPCIC is partially self-insured for workers' compensation risks. RPCIC maintains an excess workers' compensation insurance contract which limited the self-insured retention per occurrence to \$450,000. It is the opinion of management that the existing reserves and policies are adequate to provide for potential losses resulting from incidents of which management is currently aware. Additional incidents may have occurred through March 31, 2014, for which reserves have been estimated.

The charges to expense for workers' compensation related costs approximated \$3,191,000 and \$3,044,000 in 2014 and 2013, respectively, and are included as a component of employee benefits expense in the consolidated statement of revenues, expenses and changes in net position.

Matters Involving New York State: Prior to January 1, 1999, in the normal course of business, professional liability claims have been asserted against RPCIC by various claimants, and other claims may be asserted arising from services provided to patients in the past. These claims are, in substance, against the NYSDOH and are therefore, actions brought against NYS. NYS does not maintain insurance with respect to professional liability claims and is self-insured relative to medical professional liability.

Records related to professional liability claims and litigation is maintained centrally by NYS. RPCIC records the costs related to professional liability losses prior to January 1, 1999, based upon information provided by NYS Attorney General's Office. For the years ended March 31, 2014 and 2013, no payments of final settlement of malpractice cases were made.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10. LEGAL MATTERS

Regulatory Compliance: The health care industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at the time. Recently, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse statutes and regulations, which could result in the imposition of significant fines and penalties as well as significant repayments for patient services previously billed under Medicare and Medicaid programs in the current and preceding years. While certain regulatory inquiries have been made at March 31, 2014, compliance with such laws and regulations is currently subject to review and interpretation as well as regulatory actions unknown and/or unasserted at this time.

Medicare and Medicaid programs accounted for approximately 15% and 2% in 2014 and 18% and 2% in 2013, respectively, of RPCIC's net patient service revenues for the years then ended.

Litigation: RPCIC is involved in litigation arising in the normal course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse affect on RPCIC's future financial position, results from operations and cash flows.

NOTE 11. CONCENTRATION AND CREDIT RISK

RPCIC grants credit without collateral to its patients, most of whom are residents of Western New York and are insured under third-party agreements. The mix of receivables from patients and third-party payors at March 31 is as follows:

	<u>2014</u>	<u>2013</u>
Medicare	18%	18%
Medicaid	6	4
Blue Cross	26	26
Other third-party payors	45	46
Patients	<u>5</u>	<u>6</u>
	<u>100%</u>	<u>100%</u>

See Note 2 regarding maintenance of collateral accounts to limit exposure associated with Federal Deposit Insurance limits.

NOTE 12. FAIR VALUES OF FINANCIAL INSTRUMENTS

The estimated fair value amounts of RPCIC's financial instruments have been determined by using available market information and valuation methodologies. Considerable judgment is required to develop the estimates of fair value, thus, the estimates provided herein are not necessarily indicative of the amounts that could be realized in a current market exchange.

The carrying value of cash and cash equivalents, patient's accounts receivable, accounts payable, estimated third party payor settlements accrued expenses, and all other current liabilities approximates their fair value. Investments are carried at fair value using quoted market prices or estimated fair values.

RPCIC is operated as a component unit of the State of New York. DASNY issues bonds on behalf of RPCIC. DASNY has numerous separate maturities of bonds which would have to be separately valued, and, secondly, the unique circumstances affecting the State make it impractical to estimate the fair value of bonds. Additionally, considering the restrictive nature of the bond issuer, it is management's opinion that such disclosure would not enhance the usefulness of the financial statements.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12. FAIR VALUES OF FINANCIAL INSTRUMENTS (CONTINUED)

Assets and liabilities recorded at fair value in the statement of net position are categorized based upon the level of judgment associated with the inputs used to measure their fair value. An asset or a liability's categorization within the fair value hierarchy is based on the lowest level of judgment input to its valuation hierarchal levels, defined by U.S. GAAP, are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities as follows:

- Level I: Valuations based on quoted prices in active markets for identical assets or liabilities that the Corporation has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Level I assets include cash and cash equivalents, debt and equity securities that are traded in active exchange markets, as well as certain U.S. Treasury and other U.S. Governments and agencies that are highly liquid and are actively traded in over-the-counter markets.
- Level II: Valuations based on quoted prices in active markets for similar assets or liabilities quoted prices in markets that are not active or for which all significant inputs are observable, directly or indirectly. Level II assets include equity and fixed income managed funds with quoted prices that are traded less frequently than exchange-traded instruments whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.
- Level III: Valuations based on inputs that are unobservable and significant to the overall fair value measurement. These are generally company generated inputs and are not market based inputs. Level III assets would include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques as well as instruments for which the determination of fair value requires significant investment management judgment or estimation.

The following tables present information about assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2014 and 2013, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

At March 31, 2014	Prices in Active Market Level I	Other Observable Inputs Level II	Significant Unobservable Inputs Level III	Total
Cash and cash equivalents	\$ 131,775,551	\$ -	\$ -	\$ 131,775,551
Assets whose use is limited:				
Cash and cash equivalents	264,608,186	-	-	264,608,186
U.S. Government and Agency Obligations	<u>13,303,672</u>	<u>-</u>	<u>-</u>	<u>13,303,672</u>
Total assets whose use is limited	<u>277,911,858</u>	<u>-</u>	<u>-</u>	<u>277,911,858</u>
Total	<u>\$ 409,687,409</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 409,687,409</u>

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12. FAIR VALUES OF FINANCIAL INSTRUMENTS (CONTINUED)

At March 31, 2013	Prices in Active Market Level I	Other Observable Inputs Level II	Significant Unobservable Inputs Level III	Total
Cash and cash equivalents	\$ 151,344,143	\$ -	\$ -	\$ 151,344,143
Assets whose use is limited:				
Cash and cash equivalents	207,093,277	-	-	207,093,277
U.S. Government and Agency Obligations	<u>12,797,653</u>	<u>-</u>	<u>-</u>	<u>12,797,653</u>
Total assets whose use is limited	<u>219,890,930</u>	<u>-</u>	<u>-</u>	<u>219,890,930</u>
Total	<u>\$ 371,235,073</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 371,235,073</u>

NOTE 13. RELATED PARTIES

New York State:

Operating Support: As discussed in Note 1, RPCIC is related to NYS by virtue of ownership and control. Annually, RPCIC receives a significant portion of its operating revenue from NYS. This support is a fundamental component of RPCIC's annual operating budget. During the years ended March 31, 2014 and 2013, operating support received from NYS amounted to approximately \$77,600,000 and \$77,600,000, respectively. RPCIC is dependent on the continuation of this financial support and forbearance of NYS to continue its operations as a National Cancer Institute designated comprehensive cancer research and treatment center.

HEAL NY: The Health Care Efficiency and Affordability Law of New Yorkers ("HEAL NY") is a program legislated by NYS to provide a mechanism to award grants for capital expenditures to healthcare providers operating within NYS. HEAL NY is promulgated under section 2818 of the New York Health Law.

For the fiscal years ended March 31, 2014 and 2013, RPCIC received from NYS approximately \$25,000,000 and \$25,000,000, respectively, under the HEAL NY program. These funds were recognized by RPCIC concurrent with the related expenditures as contributions for the purchase of property, plant and equipment in the consolidated statement of revenues, expenses and changes in net position. RPCIC is dependent on the continuation of this financial support and forbearance by NYS to continue its operations as a National Cancer Institute designated comprehensive cancer research and treatment center.

Long-Term Obligations: As further discussed in Note 7, RPCIC recognizes in its consolidated statement of net position allocated portions of DASNY bonds issued on behalf of RPCIC and other NYSDOH facilities. In this regard, scheduled debt service payments and certain other related transactions are consummated by NYSDOH on RPCIC's behalf, using RPCIC funds. In addition, from time to time, DASNY elects to extinguish or otherwise defease certain debt issuances, and in so doing, RPCIC recognizes its proportionate share of each particular transaction, including the extinguishment, as well as recognizing its portion of any gain or loss on extinguishment.

ROSWELL PARK CANCER INSTITUTE CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 13. RELATED PARTIES (CONTINUED)

Health Research, Inc.:

Health Research, Inc. is a not-for-profit corporation chartered under the laws of NYS in 1953 primarily to apply for, secure and administer gifts or grants in furtherance of the research, prevention and treatment of diseases and conditions by the NYSDOH, RPCIC and other health related entities and as such is related to RPCIC. During the year ended March 31, 2014 and 2013, RPCIC paid approximately \$6,457,000 and \$6,111,000, respectively, of expenses incurred by HRI on RPCIC's behalf. These payments relate primarily to expenses relating to the recruitment and retention of certain principal investigators ("PI's"). Additionally, approximately \$1,545,000 and \$1,762,000 of grant revenue was remitted by HRI to RPCIC in the years ended 2014 and 2013, respectively. This revenue was generated by salary recovery on medical staff paid by RPCIC. In 2010, RPCIC changed its policy and allowed salary recovery on research staff to be retained by HRI as part of the overall contribution to HRI. This amounted to approximately \$3,668,000 and \$3,994,000 in 2014 and 2013, respectively. Furthermore, certain expenses are incurred by HRI on behalf of RPCIC, and by RPCIC on behalf of HRI, and reimbursement for these expenses are not sought by either organization in the ordinary course of business. These expenses include certain items such as rent and maintenance, administrative support and other related services.

NOTE 14. COMMITMENTS AND CONTINGENCIES

Operating Leases: Future minimum lease payments under noncancellable operating leases (net of sublease rentals) are as follows:

2015	\$	745,842
2016		302,108
2017		211,010
2018		174,518
2019		95,481
Thereafter		<u>4,277,111</u>
	\$	<u>5,806,070</u>

Total expenses for rents and operating type leases were approximately \$1,867,000 and \$1,744,000 for 2014 and 2013, respectively.



**INDEPENDENT AUDITOR'S REPORT
ON SUPPLEMENTARY INFORMATION**

To the Board of Directors of the
Roswell Park Cancer Institute Corporation

We have audited the consolidated financial statements of Roswell Park Cancer Institute Corporation as of and for the years ended March 31, 2014 and 2013, and have issued our report thereon, dated June 13, 2014, which contained an unmodified opinion on those financial statements. Our audits were performed for the purpose of forming an opinion on the financial statements as a whole.

The accompanying consolidating and combining information on pages 43 through 46 is presented for purposes of additional analysis rather than to present the financial position and results of operations for the individual entities, and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Freed Maxick CPAs, P.C.

Buffalo, New York
June 13, 2014

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONSOLIDATING STATEMENT OF NET POSITION

March 31, 2014

ASSETS	Public Benefit Corporation	RPCI Oncology, PC	Carlton & Michigan LLC	Eliminations	Consolidated Total
Current assets:					
Cash and cash equivalents	\$ 131,253,377	\$ 522,174	\$ -	\$ -	\$ 131,775,551
Current portion of assets limited as to use	34,684,234	-	16,506,376	-	51,190,610
Patient accounts receivable, net	55,987,722	526,054	-	-	56,513,776
Inventories	4,911,896	104,427	-	-	5,016,323
Due from New York State and other affiliates	2,681,732	-	-	(250,000)	2,431,732
Prepaid expenses and other assets	4,323,158	318	-	-	4,323,476
Total current assets	233,842,119	1,152,973	16,506,376	(250,000)	251,251,468
Non-current assets:					
Due from affiliates	505,099	-	-	-	505,099
Assets limited as to use, net	226,055,453	10,000	655,795	-	226,721,248
Intangible assets	-	1,065,138	-	-	1,065,138
Notes receivable	21,260,833	-	-	-	21,260,833
Capital assets, net	282,942,178	30,412	14,564,080	-	297,536,670
Investment in subsidiaries	1,941,284	-	-	(1,941,284)	-
Total non-current assets	532,704,847	1,105,550	15,219,875	(1,941,284)	547,088,988
Total assets	\$ 766,546,966	\$ 2,258,523	\$ 31,726,251	\$ (2,191,284)	\$ 798,340,456
LIABILITIES AND NET POSITION					
Current liabilities:					
Current portion of long-term obligations	\$ 12,858,331	\$ -	\$ -	\$ -	\$ 12,858,331
Accounts payable and other current liabilities	17,865,414	264,577	1,944,239	(250,000)	19,824,230
Accrued expenses	82,420,940	32,137	24,817	-	82,477,894
Unearned revenue	6,027,244	-	-	-	6,027,244
Due to third-party payors	12,304,222	-	-	-	12,304,222
Total current liabilities	131,476,151	296,714	1,969,056	(250,000)	133,491,921
Long-term obligations, net of current portion	194,255,585	-	29,780,000	-	224,035,585
Post-employment benefits, net of current portion	306,109,310	-	-	-	306,109,310
Total liabilities	631,841,046	296,714	31,749,056	(250,000)	663,636,816
Net position:					
Net investment in capital assets	93,514,929	-	-	-	93,514,929
Restricted expendable	56,795,305	-	-	-	56,795,305
Unrestricted	(15,604,314)	1,961,809	(20,525)	(1,941,284)	(15,604,314)
Total Corporation net position	134,705,920	1,961,809	(20,525)	(1,941,284)	134,705,920
Noncontrolling interest	-	-	(2,280)	-	(2,280)
Total net position	134,705,920	1,961,809	(22,805)	(1,941,284)	134,703,640
Total liabilities and net position	\$ 766,546,966	\$ 2,258,523	\$ 31,726,251	\$ (2,191,284)	\$ 798,340,456

ROSWELL PARK CANCER INSTITUTE CORPORATION

CONSOLIDATING STATEMENT OF REVENUES, EXPENSES AND CHANGES IN NET POSITION
For the Year Ended March 31, 2014

	Public Benefit Corporation	RPCI Oncology, PC	Carlton & Michigan LLC	Eliminations	Consolidated Total
Operating revenues:					
Net patient service revenue	\$ 418,369,995	\$ 4,737,644	\$ -	\$ -	\$ 423,107,639
Net settlements and appeals	16,122,590	-	-	-	16,122,590
New York State support	77,600,000	-	-	-	77,600,000
Grants and contracts	1,553,541	-	-	-	1,553,541
Other operating revenue	10,239,246	371	-	-	10,239,617
Total operating revenues	523,885,372	4,738,015	-	-	528,623,387
Operating expenses:					
Salaries and wages	193,053,837	945,803	-	-	193,999,640
Employee benefits	115,519,905	134,554	-	-	115,654,459
Supplies and other services	198,489,667	3,795,941	31,849	-	202,317,457
Depreciation and amortization	34,827,375	104,863	-	-	34,932,238
Provision for malpractice	9,870,041	-	-	-	9,870,041
Total operating expenses	551,760,825	4,981,161	31,849	-	556,773,835
Loss from operations	(27,875,453)	(243,146)	(31,849)	-	(28,150,448)
Nonoperating revenues (expenses):					
Interest and other income	1,031,207	-	9,044	-	1,040,251
Interest expense	(8,787,825)	-	-	-	(8,787,825)
Loss on disposal of capital assets	(11,869)	-	-	-	(11,869)
Investment loss	(168,551)	-	-	-	(168,551)
Net nonoperating revenues (expenses)	(7,937,038)	-	9,044	-	(7,927,994)
Deficiency of revenues over expenses	(35,812,491)	(243,146)	(22,805)	-	(36,078,442)
Contributions for purchase of capital assets	37,128,875	-	-	-	37,128,875
Change in interest in net position of subsidiaries	(263,671)	-	-	263,671	-
Increase (decrease) in net position	1,052,713	(243,146)	(22,805)	263,671	1,050,433
Net position, beginning of year	133,653,207	2,204,955	-	(2,204,955)	133,653,207
Net position, end of year	\$ 134,705,920	\$ 1,961,809	\$ (22,805)	\$ (1,941,284)	\$ 134,703,640

ROSWELL PARK CANCER INSTITUTE CORPORATION

COMBINING STATEMENT OF NET POSITION FOR THE PUBLIC BENEFIT CORPORATION

March 31, 2014

ASSETS	Roswell Park Cancer Institute	Roswell Park Cancer Institute Clinical Practice Plan	Eliminations	Public Benefit Corporation Combined Total
Current assets:				
Cash and cash equivalents	\$ 125,180,131	\$ 6,073,246	\$ -	\$ 131,253,377
Current portion of assets limited as to use	30,631,605	4,052,629	-	34,684,234
Patient accounts receivable, net	49,720,506	6,267,216	-	55,987,722
Inventories	4,911,896	-	-	4,911,896
Due from (to) New York State and other affiliates	6,964,949	(382,743)	(3,900,474)	2,681,732
Prepaid expenses and other assets	3,905,034	418,124	-	4,323,158
Total current assets	<u>221,314,121</u>	<u>16,428,472</u>	<u>(3,900,474)</u>	<u>233,842,119</u>
Non-current assets:				
Due from affiliates	-	505,099	-	505,099
Assets limited as to use, net	201,222,153	24,833,300	-	226,055,453
Notes receivable	21,260,833	-	-	21,260,833
Capital assets, net	282,911,186	30,992	-	282,942,178
Investment in subsidiaries	1,941,284	-	-	1,941,284
Total non-current assets	<u>507,335,456</u>	<u>25,369,391</u>	<u>-</u>	<u>532,704,847</u>
Total assets	<u>\$ 728,649,577</u>	<u>\$ 41,797,863</u>	<u>\$ (3,900,474)</u>	<u>\$ 766,546,966</u>
LIABILITIES AND NET POSITION				
Current liabilities:				
Current portion of long-term obligations	\$ 12,858,331	\$ -	\$ -	\$ 12,858,331
Accounts payable and other current liabilities	16,076,429	1,788,985	-	17,865,414
Accrued expenses	78,009,697	4,411,243	-	82,420,940
Unearned revenue	6,027,244	-	-	6,027,244
Due to third-party payors	12,304,222	-	-	12,304,222
Due to affiliates	-	3,900,474	(3,900,474)	-
Total current liabilities	<u>125,275,923</u>	<u>10,100,702</u>	<u>(3,900,474)</u>	<u>131,476,151</u>
Long-term obligations, net of current portion	194,255,585	-	-	194,255,585
Post-employment benefits, net of current portion	306,109,310	-	-	306,109,310
Total liabilities	<u>625,640,818</u>	<u>10,100,702</u>	<u>(3,900,474)</u>	<u>631,841,046</u>
Net position:				
Net investment in capital assets	93,483,937	30,992	-	93,514,929
Restricted expendable	27,909,376	28,885,929	-	56,795,305
Unrestricted	(18,384,554)	2,780,240	-	(15,604,314)
Total net position	<u>103,008,759</u>	<u>31,697,161</u>	<u>-</u>	<u>134,705,920</u>
Total liabilities and net position	<u>\$ 728,649,577</u>	<u>\$ 41,797,863</u>	<u>\$ (3,900,474)</u>	<u>\$ 766,546,966</u>

ROSWELL PARK CANCER INSTITUTE CORPORATION

COMBINING STATEMENT OF REVENUES, EXPENSES AND CHANGES IN
NET POSITION FOR THE PUBLIC BENEFIT CORPORATION
For the Year Ended March 31, 2014

	Roswell Park Cancer Institute	Roswell Park Cancer Institute Clinical Practice Plan	Eliminations	Public Benefit Corporation Combined Total
Operating revenues:				
Net patient service revenue	\$ 370,016,322	\$ 48,353,673	\$ -	\$ 418,369,995
Contributions from CPP/net settlements and appeals	15,704,154	1,844,336	(1,425,900)	16,122,590
New York State support	77,600,000	21,928,234	(21,928,234)	77,600,000
Grants and contracts	8,887	1,544,654	-	1,553,541
Other operating revenue	8,522,732	1,716,514	-	10,239,246
Total operating revenues	<u>471,852,095</u>	<u>75,387,411</u>	<u>(23,354,134)</u>	<u>523,885,372</u>
Operating expenses:				
Salaries and wages	155,151,196	59,830,875	(21,928,234)	193,053,837
Employee benefits	113,186,253	2,333,652	-	115,519,905
Supplies and other services	188,468,918	10,020,749	-	198,489,667
Depreciation and amortization	34,814,145	13,230	-	34,827,375
Provision for malpractice	9,870,041	-	-	9,870,041
Contributions to Roswell Park Cancer Institute Corporation	-	1,425,900	(1,425,900)	-
Total operating expenses	<u>501,490,553</u>	<u>73,624,406</u>	<u>(23,354,134)</u>	<u>551,760,825</u>
(Loss) income from operations	(29,638,458)	1,763,005	-	(27,875,453)
Nonoperating revenues (expenses):				
Interest and other income	968,652	62,555	-	1,031,207
Interest expense	(8,787,825)	-	-	(8,787,825)
Loss on disposal of capital assets	(7,370)	(4,499)	-	(11,869)
Investment loss	(168,551)	-	-	(168,551)
Net nonoperating (expenses) revenues	<u>(7,995,094)</u>	<u>58,056</u>	<u>-</u>	<u>(7,937,038)</u>
(Deficiency) excess of revenues over expenses	(37,633,552)	1,821,061	-	(35,812,491)
Contributions for purchase of capital assets	37,128,875	-	-	37,128,875
Change in interest in net position of subsidiaries	(263,671)	-	-	(263,671)
(Decrease) increase in net position	(768,348)	1,821,061	-	1,052,713
Net position, beginning of year	103,777,107	29,876,100	-	133,653,207
Net position, end of year	<u>\$ 103,008,759</u>	<u>\$ 31,697,161</u>	<u>\$ -</u>	<u>\$ 134,705,920</u>